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Abstract 
 
The development of screening approaches to identify novel affinity ligands has paved the 
way for a new generation of molecular targeted nanomedicines. To identify novel targeting 
ligands, several studies have demonstrated the advantages in screening one-bead-one-compound 
(OBOC) libraries. Conventional methods typically bias the display of the target protein to 
ligands during the screening process. We have developed an unbiased multiplex ‘beads on a 
bead’ strategy to isolate, characterize, and validate high affinity ligands from OBOC libraries. In 
addition, due to the advantages associated with screening OBOC libraries directly against living 
cells, we sought to combine cell-based screen methods with automated high-throughput 
technologies to facilitate the identification of novel affinity ligands. We have shown that bound 
cells can be reversibly cross-linked onto the beads, and then easily sorted through automated 
means using the Complex Object Parametric Analyzer and Sorter (COPAS) large format flow 
cytometer (purchased from Union Biometrica) without affecting the sequence deconvolution of 
peptides using matrix-assisted laser desorption/ionization-time of flight MALDI-TOF mass 
spectrometry (MS). This high throughput strategy can accelerate the discovery and generation of 
new targeting agents. 
 
Using the ‘beads on a bead’ approach, we have discovered novel peptides that do not 
contain the Arg-Gly-Asp (RGD) motif that bind αvβ3 integrin without affecting the biology of 
cancer or endothelial cells. The peptides identified here represent novel targeting agents for 
integrins that can be applied to cancer imaging without the risk of increased tumor invasion and 
metastasis. In order to target angiogenesis, we used the ‘beads on a bead’ strategy again to screen 
an OBOC library to isolate novel high-affinity peptides against EGFL7. A high-affinity peptide 
ligand, E7-p72 was shown to target cancer cells and endothelial cells in an EGFL7-dependent 
manner. This lead candidate could provide a basis for a new generation of sensitive angiogenesis 
targeting agents for imaging early cancers or delivery of therapeutics to disease sites.  
 
The expansion of our understanding of EGFL7 has also led us to identify and design 
bioactive peptides from the sequence of EGFL7 that could interfere with its function and serve as 
angiogenesis inhibitors. Particularly, one peptide, E7-C13 derived from the C-terminus of 
  
iv 
EGFL7 inhibits angiogenesis. This peptide could provide a basis for a new generation of 
therapeutic agents for locally advanced cancers. 
 
Keywords: 
One-bead-one-compound (OBOC) library, peptide, beads on a bead, αvβ3 integrin, EGFL7, 
angiogenesis, angiogenesis inhibitor 
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Chapter 1 
 
Introduction 
 
1.1 Advancement of nanotechnology 
 
 Although there has been a tremendous progress in our understanding of the basics of 
cancer biology, this advancement has not translated comparably in the clinic. This discrepancy 
may be due to the current inadequacies in the ability to selectively delivery diagnostic probes or 
cancer therapeutics to desired disease sites without affecting surrounding healthy tissues or 
organs. Ligand-mediated targeting has advanced the field of nanotechnology by enabling the 
delivery of high concentration of contrast agents to disease sites for molecular imaging, leading 
to the generation of high-contrast images with reduced noise levels to facilitate early diagnosis 
and monitoring of disease progression (as reviewed in (1)). Similarly, ligand-mediated targeting 
of nanomedicines has driven exciting new applications in cancer therapy. A major challenge that 
is facing cancer therapy is that common cancer chemotherapeutics currently used in the clinic 
including doxorubicin, cyclophosphamide and paclitaxel have little selectivity for cancer cells. 
As these drugs attack cells with high proliferation rates, treatment can lead to increased toxicities 
against normal tissues with high proliferation rates, such as the bone marrow and hair follicles 
(as reviewed in (2)). Ligand-targeted therapeutics are developed to delivery of high 
concentration of drugs directly to cancer cells that uniquely express specific antigens or 
receptors, thereby increasing the efficacy of therapy with reduced adverse side effects. The 
advancement in nanotechnology has also given rise to the development of nanotheranostics, 
multifunctional platforms that were designed to simultaneously diagnose and treat cancer (as 
reviewed in (3)). Nanocarriers usually comprise of three constitutions – a core material, an 
imaging agent and/or therapeutic payload, and a biological surface modifiers (Figure 1.1). 
Permeation enhancers can also be incorporated into the nanocarrier to transiently increase the 
penetration characteristics of tissues using substances such as surfactants and calcium chelators 
to enhance delivery of imaging or therapeutic agents into the target cells (4) (Figure 1.1). 
  
2 
Nanocarriers also protect small peptides from enzymatic degradation, leading to prolonged 
circulatory time.   
 
 
Figure 1.1 Multifunctional nanocarriers. A nanoparticle has the ability perform the following 
function: 1) Carry more than one therapeutic agent, 2) biomolecular targeting through antibodies 
or other recognition agents, 3) imaging by conjugation or co-encapsulation of contrast agents, 
and 4) biobarrier avoidance through permeation enhancers (to open endothelial tight junctions) 
and polyethylene glycol (PEG) (to avoid macrophage uptake). (This figure was reproduced from 
(1)). 
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1.2 Ligand mediated targeting 
 
 
1.2.1 Peptide-mediated targeting 
 
 The development of affinity probes for ligand-mediated targeting has advanced the field 
of molecular imaging (5-9), and directed therapy of disease (as reviewed in (10)). Affinity probes 
that have been approved for clinical use include several anti-tumor monoclonal antibodies (or 
antibody fragments), and non-antibody ligands (as reviewed in (2)). Antibody engineering and 
phage display technologies have led to the generation of monoclonal antibodies or antibody 
fragments with high degree of specificity for the target tissue (11),(12). Despite the fact that 
monoclonal antibodies have demonstrated high success in the clinic for targeting tumors (13), 
their major limitations, including immunogenicity (14), large sizes, and their non-specific uptake 
by the reticuloendothelial system (RES) (ie. liver or spleen) make them less compelling for 
inpatient use. Peptide-based affinity probes serve as an attractive alternative, as they are 
significantly smaller, easy to synthesize, have better diffusion and tissue penetration, 
demonstrate improved pharmacokinetics, and reduced interaction with the RES (15).  
 
 
1.2.2 One-bead-one-compound (OBOC) combinatorial library 
 
Despite several studies demonstrating the success of isolating therapeutic peptides from 
phage display peptide libraries (as reviewed in (15)), we chose to exploit the synthetic nature of 
one-bead-one-compound (OBOC) libraries for their ability to incorporate D-amino acids and 
other non-natural amino acids, as well as specific secondary structures and other macromolecular 
components (including nucleotides, lipids) that may enhance biological activity or confer 
enzymatic degradation (as reviewed in (6)). OBOC combinatorial peptide libraries comprise of 
80–100 µm beads. Amino-derivatized beads (such as TentaGel S resin) are used as the solid 
support and underwent several rounds of “split-mix” synthesis (as described in Figure 1.2), 
resulting in the display of only one chemical entity on each bead (16). This synthesis is 
extremely easy and efficient, since thousands to billions of peptides or small molecules can be 
prepared in less than a week. The library is screened against a biological target for the isolation 
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of affinity probes or bioactive ligands using a number of different assays (as reviewed in (17)). 
Positive hit beads containing high affinity ligand for the target protein can then be isolated for 
sequencing. 
 
 
 
 
Figure 1.2. Schematic of the “split-mix” synthesis strategy. Generation a one-bead-one-
compound (OBOC) combinatorial peptide library. (This figure was adapted from (18)).  
 
 
 This dissertation describes the strategies that we have designed and utilized to rapidly and 
accurately discover novel peptides for the development of new molecular imaging agents. As 
metastasis contributes to greater than 90% of cancer mortalities, non-invasive detection of 
angiogenic factors expressed during the earliest stages of tumor development can aid in the 
diagnosis of neoplasms before they metastasize. My research goals involve screening OBOC 
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combinatorial peptide libraries against different cell surface proteins that are expressed during 
the earliest stages of cancer development. 
 
Most high-throughput strategies to screen OBOC libraries utilize tagged or fluorescently 
labeled soluble biological targets (19-21). Although these techniques have been proven 
successful, soluble target proteins need to be purified and derivatized prior to screening, which 
could potentially impair the conformation and function of the native target protein (22). In 
addition, proteins displayed on cellular surface, or proteins that formed complexes with other cell 
surface proteins may have several unexposed epitopes, allowing only certain sites of the protein 
to be available for targeting. These limitations highlight the attractiveness of using cell-based 
assays to screen OBOC libraries (as reviewed in (6)). Several studies have demonstrated much 
success in using whole cell binding assays to screen OBOC libraries to isolate ligands specific to 
cell surface receptors of numerous human cancer cell lines (23), ie. Jurkat T-leukemia cells (24), 
T-lymphoma cell (25), and breast cancer cells (26). Nonetheless, conventional methods for 
isolating few positive hits from billions of OBOC library beads through manual techniques 
remain impractical and challenging. The COPAS (Complex Object Parametric Analyzer and 
Sorter) large particle biosorter (purchased from Union Biometrica) carries great potential for 
high-throughput and rapid isolation of surface binding ligands from a random OBOC library. 
However, the biggest challenge associated with this strategy is the dissociation of cells from the 
beads upon flowing them through the tubes of the instrument. Currently, there have been no 
studies to combine on-bead cell-based screening approaches `with automated sorting.  
 
 
1.2.3 Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass 
spectrometry (MS) 
 
 Peptide sequences that are isolated from OBOC libraries can be determined through 
either Edman degradation (27) or mass spectrometry (MS) techniques (ESI (28) and MALDI (29, 
30)). Edman degradation is a sequencing method that involves the labeling of the amino-terminal 
residue with phenylisothiocynate under mildly basic conditions. Under acidic conditions, the 
amino-terminal residue is cleaved as a thiazolinone derivative, which can be extracted, stabilized 
and identified using chromatography or electrophoresis approaches (27). While Edman 
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degradation is a widely used sequencing approach, the high cost per sample of this technique 
hinders its application in sequencing large amount of samples from a library screen. MS is a 
sequencing technique that measures the mass-to-charge ratio of an ionized molecule (as reviewed 
in (31). MALDI-MS is typically utilized for analysis of relatively simple peptides, while ESI is 
more commonly used for analysis of more complex samples. MALDI is often coupled to TOF to 
measure the mass of intact peptides by measuring the time it takes for an ionized fragment to 
reach a detector at a known distance (as reviewed in (31, 32). A major disadvantage associated 
with MS approaches is that they are intrinsically non high-throughput techniques due to the need 
of a two-step process: cleavage of the peptide from the resin, followed by MS analysis. We have 
previously reported a high-throughput, inexpensive and reproducible peptide sequencing 
approach using a MALDI-TOF/TOF instrument to combine photochemical cleavage of peptide 
from its solid support, its desorption-ionization, and generation of its fragmentation patterns for 
full sequence deconvolution all in one step (33). This analytical tool that we have established 
aided in the determination of small peptides without the need for complex derivatization or 
labeling, and is continuously utilized to facilitate the discovery of novel affinity peptide ligands 
for targeting cancers (34).  
 
 
1.3 Overview of angiogenesis 
 
 Blood vessels form very extensive and complex networks that are essential for the 
transport of gasses, fluid, nutrients and circulating cells between tissues and organs. In cancer, 
capillaries sprout and branch into larger and more complex networks to increase blood transport 
into growing tissues through a process known as angiogenesis (as reviewed in (35)). This 
remodeling process is most common during early embryogenesis, and is also important for the 
growth of blood vessels during physiological angiogenesis (ie. during would healing) and 
pathological angiogenesis (ie. during tumor development) in adults.  
 
Angiogenesis is tightly regulated by several signaling molecules including the vascular 
endothelial growth factor (VEGF) (as reviewed in (36)) (Figure 1.3). The composition of the 
extracellular matrix (ECM) around the vasculature also plays a role in regulating angiogenesis 
through the release of VEGF isoforms, as well as the modulation of physical contact between 
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endothelial cells and pericytes (Figure 1.3) (37). During angiogenesis, some endothelial cells that 
are selected for sprouting, known as tip cells, lead the growing sprout towards gradients of 
VEGFA (Figure 1.3). Sprout extension can be promoted via the migration of endothelial cells 
behind the tip, or proliferation of local endothelial cells (38), (39). Inhibition of Notch signaling, 
or inactivation of its ligand delta-like 4 (Dll-4) promote increased the formation of tip cells, 
leading to enhanced sprouting and branching of endothelial tubes (40),(41),(42),(43). The 
expression of Dll-4 is induced in response to VEGFA, while Notch activation suppresses the 
expression of VEGFR-2, indicating that Dll-4 acts as a negative feedback regulator to prevent 
overexuberant angiogenic sprouting (41),(43, 44). It is also possible that Notch activation in 
neighboring endothelial cells inhibit pro-angiogenic responses (Figure 1.3).  
 
Endothelial sprouts undergo many further steps to transform into functional blood 
vessels. In order to establish blood flow, vascular lumen is required to form. This process could 
take place in growing endothelial cells before or after merge with other vessels. Although the 
exact mechanism of this process is still unclear, there is strong evidence suggesting that the 
lumen of endothelial cells is formed by intracellular, and subsequently intercellular fusion of 
large vacuoles within the vessels (45). The generation of a lumen permits blood flow and 
improves oxygen delivery, thereby reducing the level of hypoxia-inducible factors (HIFs), 
leading to a lower of local VEGFA concentration. This process, along with the recruitment of 
pericyte and reduced endothelial cell proliferation promotes vessel maturation and quiescence 
(Figure 1.3).  
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Figure 1.3. Molecular regulation of angiogenesis. (a) Angiogenic sprouting is modulated by 
the balance of pro-angiogenesis signals (such as vascular endothelial growth factor (VEGF)), 
and factors that promote quiescence (such as tight pericyte contact, specific extracellular matrix 
(ECM) molecules or VEGF inhibitors). Under favorable conditions, some endothelial cells 
sprouts (green), while others do not respond (grey). (b) Endothelial cells sprout toward VEGF 
gradients. Other signals include attractive or repulsive matrix cues, as well as cells in the 
environment controls the growth of the sprout. (c) Fusion of adjacent sprouts through adhesive 
interactions when tip cells encounter each other. (d) Fusion of endothelial cells to establish a 
continuous lumen. Hypoxia-induced pro-angiogenic signals are reduced as a result of improved 
oxygen delivery. Maturation processes such as junction stabilization, matrix deposition and 
pericyte attachment also take place. (This figure was adapted from (27)). 
 
 
1.3.1 Tumor angiogenesis 
 
 During pathological situations such as cancer, angiogenesis signaling pathways are 
induced to provide the growing tumor with blood (46). In order to stimulate angiogenesis, tumor 
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cells tilt the balance towards pro-angiogenic factors to induce vascular sprouting by attracting 
cells within the tumor microenvironment (as reviewed in (47). For endothelial cells to adopt an 
activated phenotype, a variety of angiogenesis factors induce the detachment of endothelial cells, 
followed by sprouting and tube formation toward gradients of pro-angiogenic factors, leading to 
perivascular cells recruitment to provide vessel maturation, and ultimately, vascular remodeling 
to form a fully functional network (as reviewed in (48)).  
 
In cancer, multiple pathways are involved in regulating angiogenesis in order to promote 
disease progression. Once tumor growth exceeds a few millimeters in size, oxygen and nutrient 
deprivation induces the ‘angiogenic switch’ to enable the tumor to progress. Tumor cells release 
growth factors (such as VEGF) into the microenvironment to activate quiescent cells around 
them to become angiogenic. Although this process initially supports the growth of the tumor, the 
continuously remodeled tumor vessels are leaky and tortuous, leading to irregular blood flow and 
ultimately, poor tumor response (as reviewed in (49). The sustained release of platelet-derived 
growth factor (PDGF) contributes to the recruitment of perivascular cells. Although perivascular 
coverage plays an important role in vascular maturation and stability, it does not lead to the 
production of fully functional vessels, as these vessels are constantly exposed to ceaseless 
stimulatory signals within the tumor microenvironment (as reviewed in (50)).  
 
In response to hypoxia, the tumor releases a variety of factors that affect their 
microenvironment through ECM remodeling in order to accommodate tumor growth and 
progression. Integrins and receptors that are present on the surface of endothelial cells recognize 
and bind these factors to initiate signaling pathways that lead to migration, invasion, and 
proliferation that are important for sprouting. Integrins are the main cell-adhesion molecules that 
are responsible for transducing information from the ECM by triggering intracellular signaling 
pathways (51). Upon binding to a specific matrix protein, signaling mechanisms are used to 
determine whether a particular microenvironment is suitable for survival, migration and invasion 
(as reviewed in (47)). 
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1.4 The role of αvβ3 integrin in tumor angiogenesis   
 
 αvβ3 integrin consists of a 145 kDa 〈v and a 92 kDa β3 subunit. αvβ3 integrin interacts 
specifically with numerous ECM proteins (including vitronectin, fibronectin and fibrinogen) 
through an Arg-Gly-Asp (RGD) tri-peptide motif (52, 53). αvβ3 integrin is most highly expressed 
on angiogenic blood vessels and in remodeling and pathological tissues (47, 54) (Figure 1.4). 
This expression pattern allows for the development of multiple strategies to detect, monitor and 
treat angiogenesis-related pathologies. Multiple strategies have used the RGD-targeted 
nanoparticles to specifically deliver imaging and therapeutic agents to tumor-associated blood 
vessels (55). Targeted delivery of anti-angiogenic agents to tumor-associated vessels leads to 
regression of the endothelial cells and reduction of established primary and metastatic tumors 
(56). The inhibition of αvβ3 integrin function using monoclonal antibodies, RGD peptides and 
peptidomimetics has been shown to hamper angiogenesis and promote endothelial cell apoptosis 
(as reviewed in (57). Due to the fact that αvβ3 integrin expression is a general feature of 
endothelial cell activation, and not exclusive to angiogenic vessels associated with cancer, 
treatments that exploit αvβ3 integrin inhibition also affect other processes such as wound repair 
(58) and arthritis (59).  
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Figure 1.4. The expression of αv integrins on various cell types and their contribution to 
angiogenesis and tumor progression. Endothelial cells undergoing sprouting angiogenesis 
express unique integrin profiles, which can be targeted for imaging and drug delivery. Tumor 
cells alter their integrin expression profile to facilitate migration, invasion, metastasis and 
survival in hostile environments. Integrin signaling on fibroblast cells leads to the production of 
ECM proteins and growth factors that fills the tumor stroma. Proteolytic degradation of ECM 
proteins leads to the generation of fragments that can bind and inhibit the function of integrins 
that are present on angiogenic endothelial cells. (This figure was adapted from (47)). 
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1.5 Epidermal growth factor-like domain 7 (EGFL7) 
 
1.5.1 Structure of EGFL7 
 
My research also focuses on the epidermal growth factor-like domain 7 (EGFL7), a ~30 
kDa protein that is expressed at very low levels in quiescent endothelium, but is dramatically up-
regulated upon onset of physiological angiogenesis (ie. during embryogenesis, wound healing 
and in the uterus during pregnancy) (60) and pathological angiogenesis upon arterial injury (60), 
hypoxia (61), and in solid tumors (62). EGFL7 is also expressed in neurons of adult mice and 
primordial germ cells (63), (64). EGFL7 expression correlates with poor prognosis in malignant 
glioma, hepatocellular carcinoma and non-small cell lung cancer (65),(66),(67). EGFL7 contains 
an N-terminal signal secretion peptide, followed by an Emilin (EMI) domain and two EGF-like 
repeats (68),(62) (as depicted in Figure 1.5). The presence of these domains indicates that EGFL7 
is a secreted protein that forms multimeric complexes and incorporates into the ECM through 
protein-protein interactions (69),(70). EGFL7 is found to mainly localize to the ECM of cells 
(71), making it an ideal imaging biomarker for clinically relevant neoplasms and metastases.  
 
 
 
 
 
 
 
Figure 1.5. Structural organization of EGFL7. EGFL7 contains an N-terminal signal secretion 
peptide, an EMI domain, two EGF-like repeats and a C-terminal coiled-coil structure. (This 
figure was adapted from (72)).  
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1.5.2 Function of EGFL7 
 
Several recent studies reveal that EGFL7 controls vasculogenesis (embryonic formation 
and differentiation of the vascular system) and angiogenesis (formation of new blood vessels 
from pre-exisiting vessels) by creating a permissive environment for angiogenesis 
(62),(60),(71),(73). Although the exact mechanism of EGFL7 is not known, it is postulated that 
EGFL7 functions to promote the proliferation, sprouting, migration and invasion of endothelial 
cell (74) (Figure 1.6a). EGFL7 knockdown in human primary endothelial cells leads to the 
inhibition of endothelial cell proliferation, migration and sprouting (75). Additionally, EGFL7 
serves as a chemoattractant for endothelial cells, and promotes endothelial cell adhesion 
(62),(60). It may also be possible that EGFL7 remodels the ECM to promote endothelial cell 
migration and invasion. Because the expression of EGFL7 is localized to nascent endothelial 
sprouts, it is possible that EGFL7 is secreted by sprouting vessels and deposited in the ECM, 
thereby modulating its rigidity through the inhibition of lysyl oxidase (LOX) activity (Figure 
1.6b). EGFL7 has also been implicated to modulate angiogenesis through inhibition of the Notch 
signalling pathway (64),(75). Altogether, it appears that EGFL7 plays a crucial role in angiogenic 
growth by affecting the property of endothelial cells and signaling to the ECM environment. 
Altered levels of EGFL7 leads to abnormal blood vessel patterning and remodeling (as reviewed 
in (74)).  
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Figure 1.6. Models showing the role of EGFL7 in angiogenesis. EGFL7 is a protein that is 
secreted by sprouting vessels, and then deposited onto the ECM. (a) EGFL7 regulates endothelial 
cell sprouting, migration and proliferation. (b) EGFL7 modulates the rigidity of ECM by 
inhibiting LOX-mediated conversion of tropoelastin into elastin. (This figure was adapted from 
(74)). 
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1.6 Hypotheses 
 
1. A rapid and unbiased approach to screen OBOC libraries should facilitate the isolation of 
novel non-canonical peptides against key targets in cancer. We hypothesize that non-RGD 
peptides that target the αvβ3 integrin without affecting cancer and endothelial cell biology will 
facilitate the development of nanomedicines without risking increased tumor invasion or 
metastasis. 
 
2. Combining cell-based screening of OBOC libraries with high-throughput automated sorting of 
high-affinity ligands can accelerate the discovery novel targeting probes. We hypothesize that 
cross-linking of cells onto bead containing high affinity peptide through chemical fixation will 
prevent cells from detaching during automated sorting using the COPAS large format flow 
cytometer, and that this cross-linking will not affect the sequence deconvolution of peptides 
through MALDI-TOF/TOF mass spectrometry. 
 
3. A comprehensive analysis of tumor vasculature in prostate cancers have shown that men with 
the most irregularly shaped vessels are 17.1 times more likely to develop lethal disease. These 
vessels specifically express EGFL7. We hypothesize that molecular imaging using peptides 
targeted to EGFL7 will allow for non-invasive detection of early cancers and distant metastases. 
 
4. EGFL7 is an important regulator of angiogenesis. We hypothesize that bioactive peptides 
derived from the EGFL7 sequence will interfere with function of EGFL7 and lead to the 
inhibition of angiogenesis. 
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2.1 Abstract 
 
The development of screening approaches to identify novel affinity ligands has paved the way 
for a new generation of molecular targeted diagnostics and therapeutics. However, conventional 
high-throughput methods often involve the immobilization of the target protein in a specific 
orientation, thus biasing its display and surface exposure to ligands during the screening process. 
To address this, we have developed an unbiased multiplex ‘beads on a bead’ strategy to isolate, 
characterize and validate high affinity ligands from one-bead one-compound (OBOC) libraries. 
This scalable approach enriches for non-canonical ligands and incorporates multiple selection 
and validation parameters, including on-bead binding validation. We report the discovery of 
novel peptide ligands that target αvβ3 but do not contain the RGD motif. We demonstrate that, in 
contrast to RGD, they do not affect cancer or endothelial cell biology. This strategy is suitable 
for both laboratory-based benchtop or large scale high throughput approaches. The peptides 
identified here represent novel targeting agents for integrins that can be applied to cancer 
imaging or treatment without the risk of increased tumor invasion and metastasis. 
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2.2 Introduction 
 
The development of affinity probes for ligand-mediated molecular targeting has driven 
exciting new applications in molecular imaging (1-6), and directed therapy of disease (7). Recent 
advances in biomedical nanotechnology combine targeting molecules with therapeutic and/or 
imaging agents within a single entity, enabling their delivery directly to disease sites while 
avoiding normal tissues. This can improve imaging performance and potentially reduce the 
dangerous side effects of treatment. Affinity probes that have been approved for clinical use 
include several anti-tumor monoclonal antibodies such as trastuzumab (for treatment of breast 
cancer) (8) and bevacizumab (for inhibition of angiogenesis) (9). Despite success in the clinic, 
antibodies have several limitations that preclude their broad use, including immunogenicity (10), 
size-related tissue diffusion characteristics (11), and their non-specific uptake by the 
reticuloendothelial system (RES). Furthermore, their size and complexity makes their 
incorporation into chimeric drugs or multifunctional nanomedicines challenging. For this reason, 
peptide-based affinity probes provide a compelling alternative. Compared to antibodies, peptides 
are significantly smaller, resulting in improved diffusion and tissue penetration, demonstrate 
improved pharmacokinetics, and reduced interaction with the RES (12). Furthermore, the 
synthesis and production of peptides is straightforward and they can be engineered for improved 
stability and reduced immunogenicity. Peptide-based therapeutics are in extensive clinical use, 
and affinity peptides such as bombesin (13) and cyclic RGD peptides (14) have been 
successfully utilized as cancer homing agents. 
 
The discovery of novel peptide affinity probes has been facilitated by combinatorial 
library screening methods that have been developed in the last 15 years. Phage display libraries 
are comprised of expressed peptides on the surface of filamentous phage (15, 16). This biological 
approach, however, allows for the display of only L-amino acid peptides, which are susceptible 
to proteolytic degradation. Similarly, it is not possible to incorporate cyclic or branched 
structures using phage display methods (3). In contrast, 'one-bead one-compound' (OBOC) 
combinatorial peptide libraries are comprised of random peptides anchored to TentaGel resin 
beads that are generated using chemical synthesis (17). The synthetic nature of OBOC libraries 
allows for the incorporation of unnatural amino acids such as D-amino acids, and enables the 
  
26 
investigation of cyclic, turned or branched peptides which can confer enhanced resistance to 
proteolytic degradation, a key requirement for clinical applications.  
 
The OBOC combinatorial library approach has been utilized to discover novel peptide 
ligands for numerous human cancer targets, yet conventional strategies to manually isolate bead 
hits from the millions of library beads are impractical, labor intensive and time consuming (18, 
19). While a number of recent advancements have partially addressed this limitation (20, 21), 
typical screening approaches utilize a biased display of the target protein, whereby all surfaces of 
the protein are not equally exposed to the ligands on the library beads. A scalable and unbiased 
approach to screen OBOC libraries should facilitate the isolation of novel non-canonical peptides 
against key targets in cancer and other diseases. 
 
 To address these limitations, we developed a multiplex ‘beads on a bead’ combinatorial 
library screening approach that incorporates several important innovations that facilitates the 
straightforward identification of peptide affinity ligands for non-dominant epitopes. These 
include unbiased target protein display, iterative library bead separation by both magnetic and 
fluorescence sorting and cell-based on-bead binding validation. Incorporation of a photo-
cleavable linker into the library design enables on-bead MALDI mass spectrometric sequence 
determination, making this approach amenable to high throughput or laboratory bench top ligand 
discovery. To evaluate the effectiveness of this approach, we performed a screen for novel 
peptides targeting αvβ3 integrin.  
 
Integrin αvβ3 is a receptor for extracellular matrix proteins such as vitronectin and 
fibronectin that contain arginine-glycine-aspartic acid (RGD) tripeptide sequences (22). Because 
αvβ3 integrin is over-expressed on angiogenic endothelial cells and tumors, peptides 
incorporating RGD have been widely used in the design of imaging agents to visualize tumors 
(14), as well as a targeting moiety for cancer therapeutics (23). Radiolabeled RGD peptide has 
been successfully implemented in the clinic to detect lesions in cancer patients (24). Nonetheless, 
several recent studies have raised concerns regarding the use of RGD due to its effect on the 
biology of tumors (25). Cancer cells treated with RGD-labeled iron oxide nanoparticles lose 
intercellular contacts and have decreased cell adhesion (25). RGD-mimetic peptide and RGD-
mimetic small molecules inhibit angiogenesis (26, 27) and are currently in clinical trials for 
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cancer therapy. However, recent revelations suggest that the inhibition of angiogenesis is a 
driving force in tumor progression, which ultimately leads to increased tumor aggressiveness, 
invasiveness (28) and micrometastases (29). Therefore, it would be prudent to identify new non-
RGD peptides for imaging and drug delivery that effectively target αvβ3 without negatively 
affecting the biology of the tumor.  
 
We demonstrate here the utility of the multiplex ‘beads on a bead’ screening strategy to 
screen an OBOC peptide library for non-canonical αvβ3 targeting peptides. Through the 
incorporation of unbiased target protein display, sequential bulk and high-throughput separation, 
cell-based validation and on-bead peptide deconvolution, this approach facilitated the isolation of 
novel non-RGD peptide ligands that target the αvβ3 integrin without impacting the biology of the 
cells that express it.  
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2.3 Methodology 
 
 
Synthesis of peptides on TentaGel beads 
 
For proof of principle experiments, H-GRGDS-ANP-TentaGel, H-GKGDS-ANP-
TentaGel, and H-GAGDS-ANP-TentaGel pentapeptides were synthesized on a parallel 
automated synthesizer APEX 396 (AdvancedChemTech) using standard Fmoc chemistry. A 
photocleavable linker, N-Fmoc-3-amino-3-(2-nitrophenyl) propionic acid [Fmoc-ANP], was 
first attached onto TentaGel S –NH2 resin (0.29 mmol/g; 90µm) as per Brown and co-workers 
(30). Fmoc amine protecting groups were removed by treatment with 20% piperidine in DMF (2 
cycles) prior to coupling cycles. Amino acid couplings were carried out in DMF with 4 eq. 
Fmoc-protected amino acid, 4 eq. HBTU and 8 eq. DIPEA. Successful coupling was identified 
by a negative Kaiser test (31), confirming the absence of residual free primary amino groups. 
Between deprotection and coupling steps, the resin was thoroughly washed with DMF (5 
cycles). The removal of all side chain protecting groups from the synthesized peptides was 
accomplished by treatment with cleavage cocktail: TFA:PhOH:H2O:TIS (87.5:5.0:5.0:2.5) for 2 
h at room temperature (22 oC), under constant shaking (800-1000 rpm, IKA-VIBRAMAX-
VXR). 
 
 
OBOC peptide library synthesis 
 
A one-bead one-compound (OBOC) combinatorial library was synthesized using the 
Fmoc-ANP loaded TentaGel S –NH2 resin, as previously described. The resin was divided 
equally into 19 wells of the automated synthesizer. For each well, Fmoc deprotection was 
carried out, then a single amino acid was coupled to the resin, following the protocols outlined 
previously. The following L-amino acids were included in the creation of the OBOC library: 
Fmoc-Ala-OH; Fmoc-Arg(Pbf)-OH; Fmoc-Asn-OH; Fmoc-Asp(tBu)-OH; Fmoc-Glu(tBu)-OH; 
Fmoc-Gln-OH; Fmoc-Gly-OH; Fmoc-His(Trt)-OH; Fmoc-Ile-OH; Fmoc-Leu-OH; Fmoc-
Lys(Boc)-OH; Fmoc-Met-OH; Fmoc-Phe-OH; Fmoc-Pro-OH; Fmoc-Ser(tBu)-OH; Fmoc-
Thr(tBu)-OH; Fmoc-Trp(Boc)-OH; Fmoc-Tyr(tBu)-OH; Fmoc-Val-OH. After the coupling was 
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complete, the resin was removed from all wells, thoroughly mixed and re-distributed into the 19 
wells. Thus, split-and-mix synthesis resulted in a random OBOC octapeptide library. Removal 
of all permanent protecting groups was accomplished using trifluoroacetic acid and scavengers 
as previously described. All synthetic steps were carried out in the dark. 
 
 
Synthesis of Fluorescein-Labeled Peptides 
 
Fluorescein-labeled peptides were prepared following the general protocols outlines previously. 
Rink amide resin was used with Cys as the C-terminal amino acid, followed by the addition of 
Fmoc-Ahx-OH (amino-hexanoic acid) as a linker, followed by the amino acids for the sequence 
of either LCE62 or LCE64. Peptides were cleaved using cleavage cocktail comprised of 
TFA:EDT:TIS (95:2.5:2.5) and precipitated with cold t-butyl methyl ether. Peptides were dye-
labeled using maleimide-fluorescein, purified by preparative HPLC (RP-C18) and characterized 
by ESI+-MS: FITC-LCE62 Calc. [M+2H]2+ 808.4, found 808.4, purity >90%; FITC-LCE64 
Calc. [M+2H]2+ 801.4, found 801.5, purity >95%. 
 
 
Generation of αvβ3 integrin-coated magnetic/fluorescent screening beads 
 
Purified αvβ3 integrin (0.26 µg/µl) were biotinylated using the N-hydroxy succinimide 
biotin (Pierce, Rockford, USA) via the succinimide ester reaction. Biotinylation was performed 
using a 100-fold molar excess of biotinylation reagent and incubated on ice for 2 h. Excess 
biotinylation reagent was removed by gel filtration purification using G25-sepharose columns. 
The concentration of purified integrin was determined using the Bradford assay and the 
efficiency of biotinylation was determined via Western blot analysis.  
 
Two-micron streptavidin-coated rhodamine magnetic beads (Spherotech), hereafter 
referred to as "screening beads", were washed with phosphate buffered saline (PBS) secured 
using a strong neodymium magnet (K&J Magnetics, Pennsylvania, USA) to remove sodium 
azide. 50 µg of the magnetic beads (binding capacity 0.95 nmol/mg) were incubated with 2.3 µg 
of biotinylated αvβ3 integrin for 30 mins at 25 oC. 20 µg of biotin were added into the solution of 
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αvβ3-magnetic beads and incubated for 30 mins to block any remaining streptavidin sites. The 
αvβ3-magnetic beads were washed three times in PBS secured using a magnet. The extent of 
biotinylated αvβ3 incorporation on the magnetic beads was evaluated by Western blot analysis. 
Magnetic beads coated with αvβ3 integrin were added into NuPAGE LDS containing 50 mM 
DTT and boiled for 10 mins. The sample was loaded onto a NuPAGE Novex Bis-Tris Gel 
(Invitrogen, Burlington, Canada) and transferred onto a PVDF membrane for Western blot 
analysis using streptavidin-HRP (Invitrogen, Burlington, Canada).  
 
 
Confirmation of binding of αvβ3 integrin to TentaGel library beads 
 
To confirm the binding properties of purified αvβ3 integrin to control peptides on library 
beads, approximately 50 TentaGel beads coated with RGD, KGD or AGD peptides were 
suspended in 20 µl of binding buffer (25 mM Tris-HCl, 145 mM NaCl, 5 mM KCl, 1 mM 
MgCl2, 0.02 % Triton-X 100, pH 7.4). 0.13 µg of free αvβ3 integrin was added into the bead 
suspension and incubated for 1 h at 25 oC. The beads were then washed three times in binding 
buffer, and blocked in 5 % BSA in binding buffer for 2 h at 37 oC with occasional mixing. Beads 
were then incubated with anti-αvβ3 antibody (Millipore, Toronto, Canada) for 1 hour at 25 oC 
with gentle shaking, and then washed three times in binding buffer and incubated with the Alexa 
Fluor 647 secondary antibody (Invitrogen, Burlington, Canada) for 1 hour at 25 oC with gentle 
shaking. The beads were then washed three times in binding buffer and visualized using an 
AxioImager Z1 microscope (Zeiss Canada, Toronto, Canada).  
 
 
Proof-of-principle "beads on a bead" screen  
 
Approximately 50 RGD, KGD or AGD TentaGel beads were suspended in 100 µl of 
binding buffer. 1 µl of αvβ3 integrin-coated screening beads were added into each wells 
containing the RGD, KGD or AGD TentaGel beads and incubated for 1 h at 37 oC with constant 
shaking at 200 rpm. The bead mixtures were then washed with binding buffer to remove any 
unbound magnetic beads and visualized using confocal microscopy 
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 A cell-based binding validation was performed using two cancer cell lines. The 
expression of αvβ3 integrin by human MDA-MB-435 breast carcinoma cells (generous gift from 
Ann Chambers) expressing GFP and human HT-1080 fibrosarcoma cells expressing tdTomato 
(generous gift from Roger Tsien) was analyzed by Western blot using a β3 primary antibody 
(Abcam, Cambridge, Canada). Approximately 50 RGD, KGD or AGD TentaGel beads were 
suspended in serum-free DMEM in each well of a 6-well tissue culture plate. MDA-MB-435GFP 
and HT-1080tdTomato cells were seeded to a final concentration of 1 × 106 cells/well, and 
shaken at 50 rpm at 37 oC for 1 h. Beads were visualized using an Olympus IX70 inverted 
fluorescent microscope (Olympus, Toronto, Canada), and the number of cells attached to each 
bead was counted. Statistics were performed using a one-way ANOVA and Tukey post hoc test. 
 
β3 siRNA (sense: 5` GAAGAAUUUCUCCAUCCAAdTdT3`, antisense: 5` 
UUGGAUGGAGAAAUUCUUCdGdA3`) (32) (Sigma, Oakville, Canada) was used to 
knockdown αvβ3 integrin in MDA-MB-435GFP cells. MDA-MB-435GFP cells were seeded 
onto a 6-well plate and transfected with β3 siRNA at a final concentration of 20 nM using 
siLentFect. After 48 h, Western blot analysis of cells transfected with β3 siRNA or control 
siRNA was performed to confirm knockdown. MDA-MB-435GFP cells transfected with β3 
siRNA or control siRNA were trypsinized, resuspended in DMEM and directly incubated with 
the TentaGel library beads as described above.  
 
 
Multiplex screen for novel αvβ3 integrin peptide ligands 
 
The OBOC library beads (~1.0g) were washed twice with ethanol, and three times with 
binding buffer. A three-step screening process was utilized to obtain library beads that interacted 
strongly with αvβ3 integrin. First, the TentaGel library beads that bind non-specifically to the 
screening beads were removed by mixing the OBOC library with unconjugated magnetic beads 
for 1 h at 37 oC with constant shaking at 200 rpm. Beads that strongly associated with the 
magnetic beads (false positives) were removed by placing a strong neodymium magnet at the 
side of the vial for several minutes. Beads that did not respond to the magnet were transferred 
using a micropipette into another vial and washed five times with binding buffer. The second 
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(αvβ3 integrin specific) screen was performed by adding 50 µg of αvβ3 integrin-coated screening 
beads to the OBOC library under the conditions described above. Library bead hits were 
separated by placing a strong neodymium magnet at the side of the vial for several minutes. A 
micropipette was used to carefully transfer these library beads into another vial. This was 
repeated several times until no library beads remained that interacted with the magnet. Bead hits 
were washed three times with binding buffer. The third screen (cell-based) was performed by 
incubating the library bead hits with a mixture of MDA-MB-435GFP and HT-1080tdTomato 
cells in a 10-cm plate in serum-free DMEM for 1 h at 37 oC with constant shaking at 50 rpm. 
The beads were then washed twice with PBS, and visualized under an Olympus IX70 inverted 
fluorescent microscope. Beads that associated with the green (αvβ3 integrin expressing) MDA-
MB-435GFP cells, but not the red (αvβ3 integrin null) HT-1080tdTomato cells, were manually 
isolated using a micropipette. These beads were collected in a microcentrifuge tube, treated with 
6 M urea to remove the cells, washed several times with water, and then sequenced on-bead as 
we have previously described using MALDI-TOF/TOF mass spectrometry (33). Isomers such as 
isoleucine and leucine, as well as isobars such as lysine and glutamine are indistinguishable by 
their mass to charge ratios and must be uniquely identified using alternate methods (34). 
 
 
Cellular uptake assays  
 
Human MDA-MB-435 breast cancer cells and HT-1080 fibrosarcoma cells were 
detached using EDTA and resuspended in DMEM into microcentrifuge tubes. Cells were 
incubated with 3.3 µM of fluorescein-conjugated LCE62, LCE64, RGD and AGD peptides in 
suspension for 1 h at 37 oC. Blocking studies were conducted in the presence of 10x excess of 
non-fluoresceinated peptides. Cells were washed three times with PBS by centrifugation and 
seeded onto coverslips, washed and mounted. Images were captured using the Zeiss AxioImager 
Z1 microscope. The boundaries of cells were manually determined and the average fluorescein 
intensities within the selected region of interest were quantified using Volocity, version 4.0 
(PerkinElmer, Massachusetts, USA). All statistics were performed using a one-way ANOVA and 
Tukey post hoc test.  
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Cell adhesion assay  
 
MDA-MB-435 breast cancer cells were treated with 170 µM of LCE62, LCE64, RGD or 
AGD for 1 h in serum free DMEM at 37 oC. Cells were then washed six times with PBS and then 
permeabilized with 0.2% Triton-X. The cells were stained with DAPI, and imaged under an 
Olympus IX70 inverted fluorescent microscope. The number of cells that remained adhered to 
the plate was determined by selecting the DAPI signal and counting the selected regions using by 
Volocity, version 4.0. All statistics were performed using a one-way ANOVA and Tukey post 
hoc test. 
 
 
Endothelial morphogenesis/angiogenesis assay 
 
A 96-well plate was coated with 50 µL per well of Matrigel. After the Matrigel solidified, 
approximately 2000 human umbilical vein endothelial cells (HUVECs) were seeded onto the 
surface of the polymerized Matrigel. VEGF (10 ng/ml) and bFGF (10 ng/ml) were added into 
each well as the angiogenic stimulus. LCE62, LCE64, RGD or AGD peptide was introduced at a 
concentration of 200 µM and cells were incubated at 37°C in 5% CO2 for 6 hours. Cells were 
then visualized under an inverted microscope and endothelial tube formation was quantified by 
counting the number of branch points from each well (n = 3). All statistics were performed using 
a one-way ANOVA and Tukey post hoc test. 
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2.4 Results 
 
 
An unbiased ‘beads on a bead’ approach to screen OBOC libraries 
 
We developed a multiplex approach to exploit the ability of small (2 µm diameter) 
screening beads coated with a target protein to reversibly associate with much larger (90 µm 
diameter) TentaGel beads that comprise random OBOC libraries. In order to promote an 
unbiased display, the target protein was biotinylated incompletely to average one biotin per 
molecule. The biotinylated target protein was then adsorbed to 2 µm streptavidin beads that are 
both magnetic (due to an iron oxide core) and fluorescent (due to the incorporation of rhodamine 
dyes) (Figure 2.1a). It was expected that the mixing of magnetic/fluorescent screening beads 
coated with target protein with an OBOC library, the screening beads would associate with the 
TentaGel beads in an affinity-dependent manner (Figure 2.1a). The ligands with the highest 
affinity for the target protein could then be isolated using a variety of magnetic separation 
approaches, including bulk or flow-based methods (Figure 2.1b). Using these 
magnetic/fluorescent screening beads, peptide library hits can be further stratified using flow-
based fluorescence separation approaches. This approach is also compatible with validation 
using live cells, subsequent to which the isolated hits can be sequenced using a mass 
spectrometry technique that we have described previously (33). 
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Figure 2.1. Overview of ‘beads on a bead’ library screening approach. (a) A target protein of 
interest is chemically biotinylated and is allowed to interact with streptavidin-coated 2 µm 
magnetic beads (red) in solution. The magnetic beads-protein complex is allowed to react with 
the 90 µm peptide-coated TentaGel beads (white). High amount of magnetic beads are present on 
the surfaces of TentaGel beads coated with peptides that have a high affinity for the target 
protein compared with that coated with low affinity peptides; No magnetic beads are found on 
the surfaces of TentaGel beads coated with peptides that are non-specific to the target protein. (b) 
Positive hits can be isolated from the library using a bulk method or a high throughput method. 
The bulk method involves collecting the positive hits by placing a strong magnet at the side of 
the tube containing the library, and removing the negative beads by several washes. The high 
throughput method involves separating the positive hits from the library at a steady flow rate 
through a microfluidic channel. The magnet is used to divert the positive hits into the positive 
channel, while the negative beads are led into the negative channel by gravity.  
 
 To demonstrate the feasibility of this ‘beads on a bead’ approach, proof-of-principle 
experiments were designed to exploit the well-characterized binding of Arg-Gly-Asp (RGD)-
containing peptides to αvβ3 integrin (22). The IC50 of KGD for αvβ3 integrin is ten times higher 
than RGD, while the AGD sequence does not bind αvβ3 integrin (35). First, RGD, KGD or AGD 
peptides were synthesized on TentaGel beads. The association of purified αvβ3 integrin with 
these beads was then evaluated. Indirect immunofluorescence of the peptide-coated TentaGel 
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beads using monoclonal antibody to αvβ3 integrin confirmed that purified αvβ3 integrin 
associated most abundantly with RGD beads and less abundantly with KGD beads, while no 
αvβ3 integrin was detected on the AGD beads (Figure 2.2a). 
 
Integrin-coated magnetic/fluorescent screening beads were then generated by 
biotinylating purified αvβ3 integrin using Sulfo-NHS-LC-biotin, using stoichiometry that favored 
the addition of a single biotin per integrin. An excess of biotinylated αvβ3 integrin was then 
mixed with streptavidin-coated 2 µm magnetic/fluorescent beads and allowed to bind 
completely, followed by an excess of free biotin to saturate the streptavidin. Western blot 
confirmed that purified αvβ3 integrin was successfully biotinylated and conjugated onto 
streptavidin-coated magnetic particles (Figure 2.2b). The darker band at 92 kDa indicated that 
the β3 subunit was biotinylated to a greater extent than the 145 kDa αv subunit. As expected, the 
αvβ3-integrin coated magnetic/fluorescent beads interacted strongly with the RGD beads as 
evidenced by large numbers bound to the library bead surface. The integrin-coated screening 
beads interacted much less strongly with the KGD library beads, and did not detectably interact 
with AGD beads (Figure 2.2c). The stability and binding affinity of proteins are dependent upon 
the local salt concentration (36). To further demonstrate that the association of αvβ3-magnetic 
beads with the TentaGel beads was affinity-dependent, binding studies were conducted at several 
salt concentrations. Indeed, the number of αvβ3-magnetic beads bound to RGD or KGD beads 
decreased significantly as the salt concentration increased (Figure 2.2d).  
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Figure 2.2. Proof-of-principle ‘beads on a bead’ screen.  (a) Immunofluorescence staining of 
GRGDS, GKGDS or GAGDS pentamers synthesized on TentaGel beads using αvβ3 monoclonal 
primary antibody followed by Alexa Fluor 647 secondary antibody (red). Scale bar, 50 µm. (b) 
Western blot analysis of biotinylated purified αvβ3 integrin and αvβ3-magnetic beads. Blots were 
probed with streptavidin-HRP. Purified αvβ3 integrin was biotinylated and conjugated onto 
magnetic beads. The molecular weight of αv subunit (145 kDa) and β3 subunit (92 kDa) are 
indicated. (c) The level of association of αvβ3-magnetic beads with RGD, KGD or AGD-coated 
TentaGel beads correlated with the binding of purified αvβ3 integrin to the peptide-coated 
TentaGel beads seen in immunofluorescence staining (a). Scale bar, 50 µm. (d) Increasing 
sodium chloride concentration from 0.15 M to 1.0 M decreases number of magnetic beads 
associated with TentaGel beads. The fluorescence intensity of rhodamine-labeled magnetic beads 
on each TentaGel population were quantified using the Volocity software (Improvision). All 
statistics were performed using a one-way ANOVA and Tukey post hoc test. (e) Positive hits 
coated with magnetic beads (indicated by arrows) in a library consisting of a large population of 
negative AGD beads (n > 200) and a few positive RGD beads (n < 20). Images captured in the 
red channel show αvβ3-magnetic beads (indicated by arrows). Scale bar, 300 µm. 
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Next, the ability of this approach to effectively distinguish positive hits from an OBOC 
library was assessed by mixing integrin-coated screening beads with a test library comprised of a 
small amount of RGD beads (n = 20) and a larger population of AGD beads (n = 200). The 
identification of all of the "positive" RGD-coated library beads was straightforward using 
fluorescence microscopy (Figure 2.2e). Taken together, these proof of principle data suggest that 
our ‘beads on a bead’ screening approach could be utilized for efficient screening of OBOC 
peptide libraries. 
  
 
Live cell validation of peptide hits  
 
The native conformation of protein expressed at the cell surface can differ significantly 
from that of the purified protein (37). Thus, to ensure that peptide hits identified in a screen 
would bind target proteins in their native confirmation, a direct on-bead cell-binding assay was 
employed to further refine the hits before sequencing. In proof of principle experiments, the 
ability of RGD, KGD or AGD-coated TentaGel library beads to associate with αvβ3-integrin 
expressing and αvβ3-integrin knockdown MDA-MB-435 breast cancer cells, and αvβ3-integrin 
negative HT-1080 fibrosarcoma cells was evaluated. The expression of αvβ3 integrin in these 
cells was confirmed by Western blot (Figure 2.3a). For straightforward identification under a 
fluorescence microscope, MDA-MB-435 cells expressing cytoplasmic GFP and HT-1080 cells 
expressing cytoplasmic tdTomato were utilized. The αvβ3-integrin negative red fluorescent HT-
1080 fibrosarcoma cells did not bind to any of the peptide-coated library beads (Figure 2.3b). 
Incubation of αvβ3-integrin expressing MDA-MB-435 cells with RGD-coated library beads 
resulted in abundant binding of cells that was significantly reduced when αvβ3-integrin 
expression was knocked down (Figure 2.3b, c). Analogous to what was seen with the αvβ3-
integrin screening beads, MDA-MB-435GFP cells exhibited very weak interaction with the KGD 
beads, and no association with AGD beads (Figures 2.3b and c). These data indicate that cells 
expressing αvβ3-integrin specifically bind to the TentaGel library beads in a ligand-dependent 
manner. Furthermore, this suggests that a direct cell-on-bead binding validation step can be 
useful to refine the peptides to those with high affinity for the target protein in its native 
conformation. 
  
39 
 
 
Figure 2.3. Live cell validation of peptide hits. (a) Western blot analysis using the β3 primary 
antibody showing the expression of β3 integrin in MDA-MB-435GFP and HT-1080tdTomato 
cells, as well as the efficacy of αvβ3 knockdown in MDA-MB-435GFP cells using the β3 siRNA. 
(b) Fluorescent images showing that MDA-MB-435GFP cells had the strongest association with 
RGD TentaGel beads compared with KGD TentaGel beads. MDA-MB-435GFP cells did not 
have association with AGD TentaGel beads. Knockdown of αvβ3 integrin significantly decreased 
the number of MDA-MB-435GFP cells on RGD TentaGel beads. HT-1080tdTomato cells (red) 
did not bind to any TentaGel beads. Scale bar, 20 µm. (c) Bar graph showing the average number 
of MDA-MB-435GFP cells that associated with each bead from all peptide groups (n = 20, p < 
0.001). All statistics were performed using a one-way ANOVA and Tukey post hoc test.  
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The identification of non-canonical αvβ3-binding peptides LCE62 and LCE64 
 
To isolate novel non-canonical peptides targeting αvβ3 integrin, 1 g of an octapeptide 
OBOC library was screened using 2 µm αvβ3-integrin coated magnetic/fluorescent beads. The 
initial magnetic separation step isolated roughly 300 hits, which were subsequently refined by 
incubating them with live cells and sorting. In total, 32 library beads that bound to the surface of 
αvβ3-integrin expressing MDA-MB-435 breast cancer cells but not αvβ3-integrin negative HT-
1080 fibrosarcoma cells were isolated and sequenced using a previously described mass 
spectrometry approach (33). This resulted in the successful identification of 11 unique peptide 
sequences, one of which contained RGD (Figure 2.4a). The remaining peptides had some 
homology to one another, evidenced by a recurring motif Lys/His-X-Lys/His, where X 
represents any amino acid, which was observed in 8/10 peptides (Figure 2.4a). Four peptides that 
did not contain the RGD motif (LCE60, LCE61, LCE62 and LCE64) were selected for synthesis 
and further characterization. The binding affinity of these peptides for purified αvβ3 integrin was 
determined using surface plasmon resonance (SPR) (Supplementary Figure 2.1), and the KD 
values are presented in Table I. Interestingly, the two peptides with the highest affinity for αvβ3 
integrin, LCE62 and LCE64 (10.8 ± 1.2 nM and 4.7 ± 0.3 nM, respectively), each contained two 
Lys/His-X-Lys/His motifs, which suggests that this motif may be important for integrin binding. 
The chemical structures of LCE62 (MAFKHKAH) and LCE64 (KTKKVHSQ) are shown in 
Figure 2.4b.  
 
 
Table 2.1 Sequences of each peptide and their dissociation constants 
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Figure 2.4. The identification of non-canonical αvβ3-binding peptides, LCE62 and LCE64. 
(a) Peptide sequences from MALDI-TOF/TOF mass spectrometry. The RGD motif is shown in 
white, the Lys/His-X-Lys/His motif is indicated by black boxes. Sequences were aligned using 
the ClustalW multiple sequence alignment tool. LCE62 and LCE64 sequences are shown. (b) 
Chemical structures and sequences of LCE62 and LCE64. Structures were generated using the 
ChemDraw software.  
 
 
 
  
42 
LCE62 and LCE64 bind MDA-MB-435 breast cancer cells in a αvβ3 integrin-dependent 
manner  
 
Peptides LCE62 and LCE64 were conjugated with a fluorescent dye (fluorescein) and 
their ability to selectively bind αvβ3-expressing MDA-MB-435 breast cancer cells was assessed 
using fluorescence microscopy and flow cytometry. The uptake of FITC-LCE62 and FITC-
LCE64 by MDA-MB-435 cells was 3.5 times and 2.7 times higher respectively than that of 
FITC-AGD (Figure 2.5). Knockdown of αvβ3 integrin using β3-siRNA reduced the binding and 
uptake FITC-LCE62 and FITC-LCE64 in MDA-MB-435 cells to the same level as FITC-AGD. 
Furthermore, no significant uptake of FITC-LCE62 and FITC-LCE64 by αvβ3-integrin negative 
HT-1080 fibrosarcoma cells was observed. Taken together, these data suggest that LCE62 and 
LCE64 can be utilized to specifically target cells expressing αvβ3 integrin. 
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Figure 2.5. LCE62 and LCE64 are taken up by MDA-MB-435 breast cancer cells in a αvβ3 
integrin-dependent manner. (a) Fluorescence images showing the uptake of FITC-conjugated 
LCE62, LCE64, and AGD (control) (final concentration of 3.3 µM) by MDA-MB-435 cells. Left 
panels: FITC signal from peptide uptake (green). Right panels: merged images of brightfield 
image, nuclei staining (blue) and FITC-conjugated peptide (green). Scale bar, 10 µm. (b) Bar 
graph showing the mean FITC intensity in each cell. Measurements of the peptide uptake by 
cells were performed by selecting the perimeter of individual cells and obtaining the mean FITC 
intensity within selected regions using the Volocity software (Improvision). Data were 
normalized to AGD. The uptake of LCE62 and LCE64 were significantly higher than that of 
AGD (n = 30, p < 0.001). The uptake of these peptides were significantly reduced in αvβ3-
knockdown cells (n = 30, p < 0.001). All statistics were performed using a one-way ANOVA and 
Tukey post hoc test.  
 
 
LCE62 and LCE64 do not impact the biology of human endothelial or breast cancer cells 
 
RGD peptides or peptidomimetics have been widely used to target sites of abundant αvβ3 
integrin expression such as those found in angiogenic blood vessels (38) and tumors (39). Cancer 
cells treated with RGD peptide lose intercellular contacts and exhibit decreased cell adhesion in 
vitro (25), and peptides incorporating cyclic RGD inhibit angiogenesis in vivo (26). The 
biological impact of RGD peptides when utilized as cancer seeking agents must therefore be 
considered, as their use may lead to increased tumor aggressiveness, invasiveness (28) and 
micrometastases (29). In light of these concerns, the biological impact of LCE62 and LCE64 on 
human endothelial and cancer cells was assessed.  
 
A comparison was undertaken to determine the relative effect of LCE62, LCE64 and 
RGD on cellular morphology, cell adhesion and angiogenesis. First, MDA-MB-435 cells were 
treated with equivalent concentrations of LCE62, LCE64, RGD or AGD (negative control) 
peptides. Cells treated with RGD peptide adopted a more rounded morphology and exhibited 
fewer elongated protrusions compared with cells treated with LCE62, LCE64 or AGD (Figure 
2.6a). During live imaging experiments, the majority of cells treated with RGD peptide rounded 
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up and detached from the surface, while cells treated with LCE62, LCE64 or AGD remained 
adhered and migrated normally. Cell spreading was assessed by measuring the cross sectional 
area of the adhered cells after 1 hour. While the presence of RGD peptides significantly 
decreased cell spreading, no significant differences were observed between cells treated with 
LCE62, LCE64 and AGD (Figure 2.6b). RGD significantly reduced the adhesion of MDA-MB-
435 cells to the surface of a 96-well plate compared with AGD, while LCE62 and LCE64 had no 
effect on cell adhesion (Figure 2.6c). The impact of cyclic RGD, AGD, LCE62 and LCE64 on 
angiogenesis was investigated using an in vitro angiogenesis assay where human umbilical vein 
endothelial cells (HUVECs) are allowed to spontaneously sprout and form tubes on Matrigel in 
the presence of VEGF and bFGF. Cyclic RGD at 200 µM significantly inhibited tube formation 
compared to the AGD control, while αvβ3-integrin targeting peptides LCE62 and LCE64 had no 
effect at equivalent concentrations (Figure 2.6d and e). This demonstrates that peptides LCE62 
and LCE64 do not appreciably alter the morphology, cell spreading and cell adhesion of αvβ3-
expressing MDA-MB-435 breast cancer cells, nor do they affect the tube formation of 
endothelial cells in vitro. Taken together, these data indicate that peptides LCE62 and LCE64 
can be utilized for the targeting of αvβ3-integrin without affecting target cell biology.  
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Figure 2.6. LCE62 and LCE64 do not impact the biology of human endothelial or MDA-
MB-435 breast cancer cells. (a) Phalloidin staining showing F-actin distribution in MDA-MB-
435 cells after treatment with 170 µM of LCE62, LCE64, RGD and AGD. Cells treated with 
RGD have edges that are more rounded and decreased filopodia (indicated by short arrows) 
compared with treatment with AGD. The elongated filopodia in cells treated with AGD is also 
seen in cells treated with LCE62 and LCE64 (indicated by long arrows). F-actin distribution in 
cells treated with LCE62 and LCE64 remained unchanged when compared with cells treated 
with AGD. Scale bar, 10 µm. (b) Cross sectional area of cells after treatment with each peptide 
(as in (a)). Cells treated with RGD had significantly decreased cell spreading compared with 
treatment with AGD (p < 0.05). No difference was observed between cells treated with AGD and 
LCE62 or LCE64. Quantitation of cross-sectional area occupied by cell was performed using 
Volocity. (c) Cell adhesion assay showing that treatment of cells with RGD significantly 
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decreased the attachment of cells to the plate compared with treatment with AGD (p < 0.001), 
while no difference was observed between cells treated with AGD and LCE62 or LCE64. (d) In 
vitro angiogenesis assay demonstrating cyclic RGD inhibited human umbilical vein endothelial 
cells (HUVECs) sprouting and tube formation on Matrigel in the presence of VEGF and FGF (p 
< 0.01), while no difference was observed upon treatment with LCE62 or LCE64 compared with 
AGD. (e) The level of sprouting was quantified by counting the number of branch points formed 
by the HUVECs. All statistics were performed using a one-way ANOVA and Tukey post hoc 
test.  
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2.5 Discussion and conclusion 
 
We report here a versatile screening strategy for the discovery of novel non-canonical 
affinity ligands from OBOC libraries, and demonstrate its utility by identifying several high 
affinity 8-mer peptide ligands for αvβ3 integrin that do not contain RGD. The strength of this 
"beads on a bead" approach lies in its utilization of small magnetic/fluorescent screening beads, 
which, at 2 µm, are much smaller than the typical 90 µm TentaGel peptide library beads and can 
efficiently coat their surface. By incorporating multiple magnetic and/or fluorescence separation 
steps, this approach can be performed either on the benchtop using bulk separation techniques or 
in a more high throughput manner using automated sorting technology. An enrichment of non-
canonical epitopes can be accomplished using incomplete biotinylation of the target protein 
before it is adsorbed onto the screening beads, which promotes the display of multiple epitopes 
and serves to partially mask dominant binding motifs. In contrast to other described approaches 
that utilize antibodies (20, 21), this approach does not immobilize the protein in a single 
orientation. This screening method, coupled with recently developed high throughput sequencing 
approaches (33), provides an accurate yet affordable strategy for the discovery of novel affinity 
ligands.   
 
A significant challenge facing peptide screening approaches is the reduction or 
elimination of false positives, which is typically exacerbated by the incorporation of extrinsic 
biomacromolecules (i.e. chemicals, proteins, antibodies, viruses or cells) into the screening 
methodology (40). The utility of the biotin-streptavidin interaction to directly conjugate the 
target protein onto magnetic beads eliminates the use of other macromolecules that do not pertain 
to the screen. For target proteins that do not contain exposed lysine residues available for 
biotinylation, alternative conjugation strategies using small adaptor molecules can be employed 
(ie. aptamers). A further reduction in false positives can be achieved by performing a library 
enrichment step. This facilitates the removal of peptide library beads that interact with 
streptavidin by incubating the library with naked magnetic/fluorescent screening beads, before 
magnetic/fluorescent screening beads coated with the target protein are used to screen the 
enriched library. This additional step can be completed in less than an hour using a bulk 
magnetic separation approach with a minimal impact on workflow. False positives can be further 
reduced by incorporating an on-bead cell-based assay prior to peptide deconvolution. As 
  
48 
demonstrated here, this step can be performed to validate the binding of isolated hit beads to 
target proteins that are expressed in their native conformation on the cell surface. The approach 
can accommodate the use of populations of both target-positive and target-null cells to further 
increase the confidence of hits. This step can significantly narrow down the number of hits 
selected for subsequent analysis, and increases the prospect of attaining high affinity ligands that 
can specifically target the native conformation of the target protein on living cells.  
 
There are several strategies one can take to improve the stringency and throughput of this 
"beads on a bead" screening approach. A bulk separation approach (Figure 1a) enables a rapid 
but potentially crude isolation of hits. It can be utilized either as the principle separation method 
or in stepwise combination with other separation strategies. If bulk separation is the only method 
used to identify hit beads, several strategies can be employed to improve accuracy. For example, 
a number of low stringency separations can be conducted iteratively. Furthermore, the strength 
of the magnetic field can be modulated to either increase or reduce the stringency in order to 
obtain higher or lower affinity ligands. Increased control over the magnetic separation can be 
achieved using flow-based methods (Figure 1b). In our hands, this approach can provide 
exquisite control over the stringency of separation and can improve both the throughput and 
accuracy of sorting. The use of screening beads that are both magnetic and fluorescent allows for 
multiparametric separation. High throughput fluorescence separation of OBOC libraries can be 
accomplished using a large format sorting platform such as the Complex Object Parametric 
Analyzer and Sorter (COPAS) from Union Biometrica. While the use of this specialized platform 
for sorting bead libraries has been previously described(20), its considerable cost precludes its 
general use. Bulk magnetic separation provides a low-cost alternative that can be performed on 
the benchtop.  
 
We identified several high affinity peptide ligands of αvβ3 integrin, the majority of which 
did not contain RGD. In 8 of the 10 peptides identified that did not contain RGD, recurring motif 
Lys/His-X-Lys/His was observed. Peptides LCE62 and LCE64 had exceptional affinity for 
purified αvβ3 integrin (Table I) and were taken up by αvβ3 integrin-expressing breast cancer cells 
in an integrin-dependent manner. LCE62 and LCE64 each contain two Lys/His-X-Lys/His 
motifs, which suggests that sequences comprised of alternating basic amino acids may be 
important for integrin binding. Fibrinogen has been reported to contain at least one non-RGD 
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αvβ3-dependent adhesive site that does not play a role in the spreading of human melanoma cells 
(41). A cluster of basic amino acids in the fibrinogen sequence was found to be the binding site 
for αIIbβ3 integrin (42). It is plausible that the positively charged Lys/His-X-Lys/His-containing 
peptides LCE62 and LCE64 may recognize an analogous binding site on αvβ3 integrin. Peptide 
candidates that contain this Lys/His-X-Lys/His motif may have potential to be developed and 
utilized as αvβ3-targeting ligands, and it is possible that these ligands may be further optimized. 
There were no significant similarities detected between any of the novel αvβ3 integrin ligands 
and extracellular proteins. However, this does not preclude the possibility that LCE62 and 
LCE64 may adopt structures that mimic those possessed by other proteins that interact with αvβ3 
integrin. Taken together, our data suggests that peptides LCE62 and LCE64 recognize the 
extracellular domain of αvβ3 integrin at a site that is distinct from the active site.  
 
Since its discovery in 1985 (43) as the component of fibronectin required for cell binding, 
there has been an explosion in the use of RGD peptides for integrin-targeted imaging and drug 
delivery efforts in the experimental, pre-clinical and clinical realms. Given the well described 
anti-angiogenic activity of these peptides, the potential biological impact of their use must be 
considered. For example, a relatively high concentration (in the millimolar range) is generally 
required for drug delivery and imaging modalities such as optical or magnetic resonance imaging 
(MRI) (25, 44, 45). Imaging modalities such as positron emission tomography (PET) and single-
photon emission computed tomography (SPECT) typically require very low ligand 
concentrations (nanomolar to femptomolar) (45), and are unlikely to exert a biological effect. 
This is complicated, however, by evidence that suggests that low concentrations of RGD peptide 
can enhance tumor growth in vivo by promoting VEGF-mediated angiogenesis (46). We 
demonstrate here that LCE62 and LCE64 target cancer cells expressing αvβ3 integrin without 
altering their morphology, their ability to spread, or their adhesion. Furthermore, these peptides, 
even at high concentration (200 µM), do not inhibit angiogenesis. It will be important going 
forward to validate the biological impact of these peptides in vivo.  
 
While these novel integrin ligands (LCE62 and LCE64) effectively target breast cancer 
cells in vitro, the in vivo targeting of these peptides to αvβ3 integrin in tumors and angiogenic 
vasculature need to be evaluated. Cyclic RGD peptides (IC50 = 0.58 nM) and peptidomimetics 
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(IC50 = 12 nM) have been successfully utilized for in vivo tumor imaging (47, 48). Since LCE62 
and LCE64 have KD values comparable to that of cyclic RGD, we are optimistic that they can be 
used to target αvβ3-expressing tumors and angiogenic vessels. Thus, these novel ligands are 
promising tumor homing agents for translational applications in drug delivery, targeted MRI and 
intraoperative imaging that do not impact tumor biology.  
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3.1 Abstract 
 
The discovery of peptide ligands from one-bead-one-compound (OBOC) combinatorial 
libraries has driven advances in molecular imaging and the development of targeted 
nanomedicines. Recognition of cell surface proteins is optimally achieved using live cells, yet 
screening intact cell populations is time-consuming and inefficient. Here, we evaluate the 
COPAS large particle biosorter for high throughput sorting of bead-bound human cell 
populations for the purpose of screening. By screening a library of RGD-containing peptides 
against human cancer cells that express αvβ3 integrin, we find that bead-associated cells are 
rapidly dissociated when sorted through the COPAS instrument. However, we demonstrate that 
when the bound cells are reversibly cross-linked onto the beads, they can then be sorted quickly 
and accurately. We go on to show that this reversible cross-linking approach is compatible with 
MALDI-TOF/TOF mass spectrometry-based peptide sequence deconvolution, allowing for rapid 
screening and identification of peptide ligands from bead-based combinatorial libraries. This 
approach should facilitate the discovery of improved peptide ligands against cell surface targets 
in their native conformation. 
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3.2 Introduction 
 
 Recent advancements in nanotechnology have combined targeting molecules with 
imaging agents and/or therapeutics into a single entity, enabling their delivery to disease sites 
while avoiding healthy tissues (1-6). Peptides that are isolated from biological systems, such as 
phage display libraries, have provided many valuable targeting agents (7-10). However, the 
biological nature of these libraries limits their application to the discovery of natural peptides, 
which have increased susceptibility to proteolytic degradation under physiological conditions. 
For this reason, peptides that are discovered using these approaches can be unsuitable for in vivo 
studies (11). One-bead-one-compound (OBOC) library screening methods are a promising 
chemistry-based alternative to peptide ligand discovery, and have been used previously to 
identify novel ligands for molecular imaging (2, 12-14), protein inhibition (15, 16) and directed 
therapy of diseases (17-19). OBOC combinatorial libraries, are comprised of 90 micron-sized 
beads each bearing a unique ligand, can be synthesized using straightforward chemistries and 
screened in parallel against cell surface targets (20). The primary advantage of OBOC peptide 
libraries is the incorporation of non-natural components, such as D-amino amino acids, or the 
incorporation of cyclic, turned or branched ligands (12, 21). This facilitates the identification of 
peptide ligands that are resistant to proteolytic degradation, making them more suitable for in 
vivo applications. 
 
For the purpose of OBOC library screening, the target protein is chemically tagged or 
fluorescently labeled (22-24). While this approach is feasible for many targets, proteins must be 
purified and derivatized prior to screening. This increases the risk that these proteins would 
adopt an altered conformation and could impair their function (25). In many cases, this approach 
will not account for changes in conformation due to protein activation (26, 27). For cell surface 
proteins and/or proteins that typically form complexes with other cell surface proteins, the 
presence of the plasma membrane and binding partners may be required for proper folding and 
the display of biologically relevant epitopes. These limitations can be addressed through the 
development of cell-based assays to screen OBOC libraries. Indeed, screening approaches using 
living cells have been successfully utilized to discover ligands against human cancer cell lines 
(28), ie. Jurkat T-leukemia cells (13), T-lymphoma cell (29), and breast cancer cells (14). 
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Nevertheless, conventional methods for isolating rare positive hits from a large OBOC library 
through manual techniques remain challenging and impractical.  
 
To increase the throughput of library screening, instruments such the COPAS bead sorter 
(Union Biometrica) have been employed to isolate high affinity ligands from OBOC libraries 
using purified target proteins (30-32). In an initial evaluation of this platform to screen 
combinatorial libraries using living cells, we have found that associated cells would fall off the 
beads once they were passed through the COPAS instrument, preventing proper sorting. This is 
likely caused by a variety of factors, such as turbulence and shear forces within the instrument 
that exceeded the affinity of the target with its ligands. In this work, we have evaluated a 
reversible cross-linking method to stabilize the association of cells and the bead they are bound 
to. We hypothesize that chemical fixing of cells to their associated bead prior to insertion into the 
COPAS instrument would prevent the cells from detaching during the flow-based sorting 
process.  
 
An important element of screening throughput is the efficient deconvolution of hit 
peptides, which we have previously addressed using a MALDI-TOF/TOF mass spectrometry 
(MS) approach (33). This strategy allows one to perform the photochemical cleavage of peptide 
from the solid support, peptide desorption-ionization, and generation of fragmentation pattern in 
a single step. Our concern, however, is that chemical cross-linking might interfere with accurate 
sequence determination using mass spectrometry. To test the compatibility of reversible cross-
linking with this approach, we have performed a limited screen using αvβ3 integrin-expressing 
fluorescent cancer cells and a focused OBOC peptide library. The library is comprised of RGD 
sequences fused with a representative mixture of the remaining amino acids. After cross-linking 
the cancer cells to the library beads, the library is sorted using the COPAS instrument, and the 
resultant hits are sequenced using the on-bead MS approach. Sequence results are compared 
between peptides that are not cross-linked, peptides that are cross-linked, and peptides that are 
first cross-linked and then treated with heat to reverse the cross-links.  
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3.3 Methodology 
 
 
Peptide library synthesis 
 
Fmoc-based solid-phase peptide synthesis was carried out using an APEX 396 
autosynthesizer (AAPPTEC) with 0.05 mequiv of 0.26 mmol/g TentaGel S NH2 (0.27 mmol/g) 
resin. A threefold excess of Fmoc-ANP and subsequently, the protected amino acids was used in 
coupling reactions. Fmoc removal was carried out using a solution of 20% piperidine in DMF 
(N,N-dimethylformamide) over two cycles (10 and 20 min). Amino acid activation was carried 
out with three equivalents of HBTU and six equivalents of DIPEA (N,N- 
diisopropylethylamine), which was followed by amino acid coupling over 30 and 120 min 
cycles. Deprotection of peptide side chains was accomplished using a solution of 88% TFA (v/v) 
+ 5% H2O (v/v) + 5% phenol (m/v) + 2% triisopropylsilane (v/v) over 6 h. 
 
 
OBOC library screening using live cancer cells 
 
αvβ3 integrin-expressing MDA-MB-435 breast cancer cells were labeled with green 
fluorescent protein. Approximately 1 000 beads containing each peptide were equilibrated with 
serum-free DMEM in a 12-well plate. MDA-MB-435 cells were detached from the flask by 
EDTA and resuspended in serum-free DMEM. 200 000 of each MDA-MB-435 cells were added 
into each well containing the library beads and placed in a shaking incubator (50 rpm) for 1 hr at 
37oC. The beads were washed twice with PBS, and then imaged under the Olympus IX70 
inverted fluorescent microscope.  
 
 The cells were then fixed onto the beads with 4% formaldehyde for 5 minutes at room 
temperature, and washed twice with PBS.  
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Sorting of positive hits using COPAS 
 
The beads from each well were inserted into the COPAS large particle flow cytometer 
(Union Biometrica), and sorted into a 96 well plate. Firstly, the sorting threshold was established 
using TentaGel beads coated with empty TentaGel beads that have never been previously treated 
with cells. This step is necessary because TentaGel beads auto-fluoresce, especially in the green 
(excitation wavelength 488 nm) and red (excitation wavelength 561 nm) channel. The instrument 
was then gated to only analyze and isolate beads with the highest fluorescence well above the set 
threshold. This population represents beads that have the strongest association with cells. Any 
beads with fluorescent intensity higher than the set threshold were sorted into a 96-well plate. 
Beads that were isolated were imaged under the Olympus IX70 inverted fluorescent microscope. 
The beads were treated rigorously with ethanol to remove any bound cells, and washed several 
times with water.  
 
 
MALDI TOF MS/MS sequence analysis 
 
Cleavage of peptides from TentaGel beads was carried out using UV irradiation. All care 
was taken to prevent light exposure to synthesized peptides prior to ANP-linker cleavage. For 
this reaction, approximately 1-3 peptide conjugated TentaGel beads were placed in 200 µL of 
MilliQ water in an open-top 384 well polypropylene plate. UV irradiation was carried out using a 
365 nm UV lamp (UV Products, Upland, CA, model EL25, 8 mWcm−2) over 2.5 hours. Water 
was added periodically in order to prevent wells from drying, thus reducing possible peptide 
decomposition. The resulting peptide-containing solution was then used for MALDI-
TOF/TOFTM analysis.  
 
In a typical experiment, the exact molecular ion mass [M+H]+ of a peptide is determined 
using MS analysis. MS/MS spectra are subsequently recorded for the desired molecular ion peak, 
previously observed by MS. This was then followed by manual deconvolution of all peptide 
sequences in this study.  
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3.4 Results 
 
Combining automated cell-based with OBOC peptide library screen 
 
The biggest challenge associated with automated sorting of hits from screening OBOC 
libraries against living cells was that the cells dissociate from the beads upon insertion into the 
sorter. Overcoming this issue would enable an easy and high-throughput automated sorting of 
high-affinity ligands from OBOC libraries. To do this, we tested our hypothesis that bound 
fluorescent cells can be chemical cross-linked onto the library bead, and that this would prevent 
the cells from detaching throughout the sorting process. Hit peptides with the strongest affinity 
for the cells would have the highest fluorescence, and can be sorted and isolated into a 96-well 
plate (Figure 3.1). Beads that did not associate, or had low interaction with the cells were pooled 
into a sample recovery unit.   
 
The GRGDS peptide was demonstrated to bind the αvβ3 integrin with high affinity in 
several studies (34-37). As a proof-of-principle, a biased peptide library incorporating the 
GRGDS moiety and a photolabile ANP linker was synthesized, via solid phase methodology, on 
TentaGel resin. The photo-cleavable linker was utilized to enable efficient release of the peptide 
from the TentaGel bead for sequencing. The two C-terminal amino acids were randomized in 
order to better mimic a randomized peptide library. The GRGDSYT, GRGDSTW, GRGDSWK, 
GRGDSVP, GRGDSHL, GRGDSFA, and GRGDSPS peptides were synthesized onto TentaGel 
beads (Figure 3.2). Peptides were fully deprotected, while still on TentaGel, prior to fluorescent-
based analysis by COPAS biosorter. We treated the biased RGD-containing library using live 
αvβ3-expressing MDA-MB-435 breast cancer cells. These cells were labeled with green 
fluorescent protein (GFP) so that they can be easily detected or visualized under a microscope. 
Cells were incubated and allowed to associate with RGD-containing TentaGel beads. High 
binders were then sorted into a 96-well plate as shown in Figure 3.1.  
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Figure 3.1. Cell-based screening of OBOC peptide libraries to identify high affinity ligands 
to cellular targets using the COPAS biosorter. Beads incubated with live fluorescent cells are 
washed, fixed with 3% formaldehyde and loaded into the sorter. Bead hits with strong 
interactions with cells (highest fluorescent intensity) are sorted into a 96-well plate, while beads 
with few bound cells are excluded.    
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Figure 3.2. Design of focused library of integrin-binding peptides. GRGDS-containing 
heptameric peptides were synthesized onto TentaGel beads via a photo-cleavable linker. 
Different residues (indicated in blue) represent different amino acids that were tested. 
 
 
Proof-of-principle: Cross-linking associating cells to beads facilitates automated large 
particle sorting 
  
 αvβ3 integrin-expressing MDA-MB-435 breast cancer cells labeled with GFP were 
incubated with each species of the RGD-containing beads. Although MDA-MB-435 cells 
associated with all the beads, the two additional amino acids at the C-terminus affected the 
affinity of each peptide with the cells (Figure 3.3a and Supplementary Figure 3.1). MDA-MB-
435 cells interacted most strongly with the GRGDSWK, GRGDSPS and GRGDSFA peptides, 
while showing moderate association with the remaining peptides (Figure 3.3a and 
Supplementary Figure 3.1). The beads were then washed with phosphate buffer saline (PBS) to 
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remove any unbound cells, and cells that were tightly associated with the beads were fixed with 
3% formaldehyde so that they remained attached during and after the sorting process (Figure 
3.3a and Supplementary Figure 3.1). Although cross-linking is necessary to maintain the 
association of MDA-MB-435 cells with the bead throughout the automated sorting process, this 
step may be omitted when using “stickier” cells, such as fibroblast. To distinguish between the 
bead and cell populations, TentaGel beads alone or MDA-MB-435 GFP cells were incorporated 
separately into the COPAS flow cytometer, and their sizes and optical density were evaluated 
(Figure 3.3b). The bead population appeared in the top right quadrant, while majority of the cell 
population appeared in the bottom left quadrant (Figure 3.3b). To establish the gate and sorting 
threshold, TentaGel beads coated with a negative control peptide that has undergone cell 
treatment, fixation and washes were incorporated and analyzed in the COPAS instrument. As 
TentaGel beads auto-fluoresce, the sorting gate was set to sort beads with cells bound onto them 
that have higher fluorescent intensities than the large population of the control beads (Figure 
3.3c). Although it was indicated that 12.5% of beads were sorted, microscopy analysis revealed 
that this population consisted of bare beads with abnormally high autofluorescence that did not 
have cells bound onto them (data not shown). Approximately 68% of GRGDSPS beads were 
sorted, and microscopy analysis revealed that these beads were completely coated with cells 
(Figure 3.3a and c). Using the same procedures, we sorted the remaining test GRGDS-containing 
TentaGel beads. The GRGDSWK and GRGDSFA peptides also had high affinity for MDA-MB-
435 cells, with a sorting rate of 80.3% and 48%, respectively (Supplementary Figure 3.2). The 
GRGRDSYT, GRGDSHL, GRGDSTW and GRGDSVP have relatively weaker associations 
with MDA-MB-435 cells, resulting in sorting rates of less than 30% (Supplementary Figure 3.2). 
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Figure 3.3. Establishing the sorting parameters for library beads coated with intact cells. 
(a) TentaGel beads containing GRGDSPS peptide incubated with MDA-MB-435 GFP cells (left) 
and fixed with 3% formaldehyde (right). Beads with the highest association for cells were sorted 
using the COPAS instrument. (b) Dot plot showing the bead or cell population. EXT represents 
extinction (measurement of total light scatter), TOF stands for time of flight, and FLU1 
represents the green fluorescence intensity. (c) Dot plot showing the cell-bead populations and 
their sorting profiles. The upper panel shows the two distinct bead and cell population (indicated 
by arrows) and the beads were gated for sorting. The bottom panel shows the green fluorescence 
intensity of each bead (gated from the upper panel). The sort gate was established using negative 
control TentaGel beads that has undergone cell treatment, fixation and washes so that only beads 
with cells attached (higher fluorescent intensities) were sorted. GRGDSPS-TentaGel beads with 
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MDA-MB-435 GFP were then inserted into the COPAS instrument, and beads with the highest 
association with cells were sorted into a 96-well plate.  
 
 
Confirmation of MALDI-TOF/TOF peptide sequence deconvolution pre- and post- sorting 
 
Samples of all peptides in the library, at pre- and post sorting stages, were completely 
deprotected and cleaved for MALDI-TOF analysis. Similar signal to noise ratios of obtained 
mass spectra as well as the subsequent complete deconvolution of all peptide sequences, pre- and 
post-sorting (Figure 3.4 and Supplementary figure 3.3), proves that cross-linking cells onto beads 
stabilizes their association for automated sorting and does not prevent sequencing through mass 
spectrometry approaches. Therefore this approach enables a viable and versatile high-throughput 
screen of peptide libraries. 
 
 
 
 
Figure 3.4. On-bead MALDI-TOF/TOF MS sequencing of peptide before and after 
fixation. MS/MS spectra of H-GRGDSPS-NH2 before fixing with formaldehyde (left), and after 
fixing plus sorting (right). Peptide sequences from both samples were successfully attained. 
Fragments labeled bja and yja were calculated by complementarity. 
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3.5 Discussion and conclusion 
 
Here, we demonstrate the usefulness of a reversible cross-linking method to improve the 
association of cells and high-affinity ligand-containing beads during an automated sorting 
process. MDA-MB-435 breast cancer cells expressing GFP are incubated with each type of the 
RGD-containing library bead, and the cells are then cross-linked onto their associated beads. 
Positive hit beads with bound cells display much higher fluorescent intensities compared to 
negative empty beads, and can be sorted individually into each well in a 96-well plate. We also 
show that the cross-linking step does not prevent us from accurately obtaining the sequences of 
our test peptides through MS approaches.  
 
The pentameric GRGDS sequence is incorporated into all test peptides. Two common 
natural amino acids are incorporated at the end of the test sequences to closely mimic a random 
combinatorial library. The cysteine residue is excluded from the test peptides to avoid the 
formation of disulfide linkages, while methionine is omitted to avoid potential oxidation. 
Isoleucine is also excluded because it is isobaric to leucine, rendering them indistinguishable 
from one another by MALDI MS. Similarly, glutamine is excluded from the test peptides 
because it is isobaric to lysine. We found that the composition of the last two amino acids 
significantly affect the binding affinity of the peptides to cells. This observation is consistent 
with other studies that demonstrated that different residues flanking the RGD motif of proteins 
can significantly alter their binding specificity and affinity to integrins (38-40).  
 
Even though other studies have demonstrated the success in isolating peptides from 
screening an OBOC library using cells (14, 41), the process of isolating positive hits manually is 
a time consuming and challenging. The COPAS large format biosorter enables us to accurately 
execute high throughput automated sorting at up to 300 beads per second, allowing the entire 
screening process to be completed in less than a week. Although other studies have demonstrated 
the benefits of incorporating magnetic isolation in a cell-based screening process using 
antibodies (42), these methods pose an immense risk of attaining a large number of false 
positives that bind non-specifically to the extrinsic biomacromolecules that are present on the 
surface of the magnetic beads. Our study relies solely on the interaction between the cells and 
peptide-coated library beads, therefore decreasing the risk of isolating false positives caused by 
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other non-specific interactions. To further optimize the specificity of our screen, one can enrich 
the library by first using knockout/knockdown cells before screening with cells that express the 
target protein. This process can eliminate false positives by decreasing the chances of isolating 
ligands that bind to other surface receptors that are normally present on a particular cell. 
 
We have initially encountered many challenges associated with the cells detaching from 
their associated bead, most likely due to mechanical forces as it passes through the flow cell. As 
a result, very few beads displayed cells by the time they were detected for sorting. Cross-linking 
cells to the bead they are bound to with formaldehyde prior to sorting significantly improves the 
attachment of cells on the bead throughout the sorting process. Although we have demonstrated 
that treating the beads with formaldehyde does not impede MALDI MS sequencing, we have 
nonetheless, attempted to reverse the cross-links by heating the beads to 60oC for 10 minutes, 
and then 95oC for 15 minutes. However, we have shown that reliable mass spectrometry spectra 
could not be consistently obtained from beads that have undergone heat treatment.  
  
One other major challenge that we have encountered during the sorting process is the 
inability of the COPAS instrument to distinguish the fluorescence emitted by bound cells from 
the auto-fluorescence that are naturally produced by the library beads. Nonetheless, this 
limitation can be easily overcome by direct visual examination through fluorescence microscopy 
after sorting has been completed.  
 
This method can accommodate the use of both target-positive and target-null cells to 
further increase the confidence of isolated hits. Not only can this significantly narrow down the 
number of hits selected for subsequent analysis, but it can also increase the prospect of obtaining 
high affinity ligands that specifically target the native conformation of the target protein on 
living cells. The use of this technique can also be very advantageous for screening for ligands 
against cell surface receptors that adopt very specific conformations in living cells. Surface 
receptors typically adopt diverse conformations under various conditions. For example, a 
decrease in extracellular pH causes conformation changes in integrins, which facilitate their 
activation (43). Additionally, ligand binding regulates the function of several extracellular 
surface receptors, i.e. G-protein-coupled receptors (44) through the establishment of new 
conformational equilibrium. We can further expand the scope of our study to using induced cells 
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to screen for ligands specific for only activated receptors. Ultimately, there is a vast potential for 
our findings to be further augmented for applications in personalized medicine by screening for 
ligands specific for cells (i.e. localized vs. metastatic cancers) collected from patients.  
 
Our results show that we can easily and reliably perform automated screening of very 
large OBOC combinatorial libraries by fixing live cells onto the bead that they are bound to, and 
that we are able to isolate and sequence high-affinity ligands in a high-throughput manner within 
a short period of time. Our findings can help accelerate the rate for isolating targeting ligands 
that can be applied for the purpose of molecular imaging and drug delivery.   
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4.1 Abstract 
 
As a tumour grows beyond 1mm, it generally recruits new blood vessels through the 
process of angiogenesis. Metastasis is the cause of 90% of cancer mortalities, and targeting areas 
of active angiogenesis should aid in suppressing tumours before they metastasize. Epidermal 
growth factor-like domain 7 (EGFL7) is protein that is dramatically up-regulated in the 
endothelium of tumours. EGFL7 expression correlates with poor prognosis in malignant glioma, 
hepatocellular carcinoma and non-small cell lung cancer. Although the function and mechanism 
of action that EGFL7 is involved in currently not well understood, it is an important biomarker 
for clinically relevant neoplasms and metastases. Here, we describe the identification and 
characterization of novel anti-EGFL7 peptide ligands from screening a combinatorial peptide 
library using a novel ‘beads on a bead’ approach. We discovered a novel EGFL7 ligand, E7-p72 
that was shown to have high affinity for EGFL7. A strong uptake of fluorescein-conjugated E7-
p72 was observed in human EGFL7-expressing cancer cells and endothelial cells. We also 
demonstrated that CPMV nanoparticles coated with E7-p72 bind to endothelial cells in an 
EGFL7-dependent manner. This peptide could provide a basis for a new generation of sensitive 
molecular imaging probes for the non-invasive diagnosis of early cancers. 
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4.2 Introduction 
 
The development of affinity probes for ligand-mediated targeting has advanced the field 
of molecular imaging (1-6), and directed therapy of disease (as reviewed in (7)). Advancement in 
nanotechnology has led to the generation of “smart” nanoparticles, allowing for the combination 
of targeting ligands with therapeutic and/or imaging agents all within a single entity. The 
development of targeted nanoparticles has enabled the delivery of high concentrations of 
imaging agents and/or drugs to disease sites while avoiding normal tissues, leading to the 
generation of high-contrast images with reduced noise levels, as well as increased efficacy of 
therapy with reduced adverse side effects. While monoclonal antibodies have demonstrated high 
success in the clinic for targeting tumors (8), they have major limitations that need to be 
addressed, including immunogenicity (9), size-related tissue diffusion properties, and their non-
specific uptake by the reticuloendothelial system (RES). Peptide-based affinity probes serve as 
an attractive alternative, as they are significantly smaller, have better diffusion and tissue 
penetration, demonstrate improved pharmacokinetics, and reduced interaction with the RES (10). 
Examples of affinity peptides that are in extensive clinical use as cancer homing agents include 
bombesin (11) and cyclic RGD peptides (12). 
 
 Strategies for screening combinatorial peptide library, such as phage display (13) and 
one-bead-one-compound (OBOC) (14) libraries have facilitated the discovery of novel peptides 
for molecular targeting. While several studies have demonstrated the success of isolating 
therapeutic peptides from phage display peptide libraries (as reviewed in (10)), we exploited the 
synthetic nature of OBOC peptide libraries as it provides several key advantages, such as 1) the 
ability to incorporate non-natural amino acids, and 2) the potential to construct cyclic, turned or 
branched peptides, all of which can confer enhanced resistance to proteolytic degradation. We 
have recently described a multiplex ‘beads on a bead’ combinatorial library screening approach 
that enables a rapid and straightforward identification of peptide affinity ligands for a specific 
target protein (4). This strategy incorporates the display of target protein on small screening 
magnetic/fluorescent beads, followed by iterative library bead separation (either by magnetic 
and/or fluorescence sorting), and on-bead cell-binding validation (4). A photo-cleavable linker 
was incorporated into the library design to enable an on-bead MALDI mass spectrometric 
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sequencing to be done in one step (15), making this an attractive approach for high throughput or 
laboratory bench top ligand discovery.   
 
 The epidermal growth factor-like domain 7 (EGFL7) is a ~30 kDa protein that is 
expressed mostly in the endothelium during embryogenesis, physiological and pathological 
angiogenesis (16-20). Importantly, EGFL7 levels are very low in quiescent endothelium, and its 
expression is substantially elevated during endothelial regeneration after vascular injury, 
indicating that EGFL7 carries an important function during angiogenesis (17-19). Increased 
EGFL7 expression is also observed in response to hypoxia cultured endothelial cells and 
neonatal rat brain in vivo (21, 22). Besides the endothelium, EGFL7 has also been detected in 
progenitor cells and neural stem cells (23, 24). Additionally, EGFL7 has also been detected in 
several tumors and cancer cell lines, including malignant gliomas, hepatocellular, breast, and 
lung carcinomas (25-27). Overexpression of EGFL7 in mice led to abnormal vasculature 
remodeling (20), suggesting the possibility that EGFL7 expression contributes to the formation 
of irregularly shaped, tortuous and leaky blood vessels. This microvessel morphology is 
characteristic of tumor angiogenesis, and is linked with cancer-specific mortality (28). In patients 
with malignant glioma, the expression of EGFL7 correlated with high tumor grade and poor 
prognosis, indicating that EGFL7 can serve as a predictor factor for the clinical progression of 
the disease (25). Therefore, affinity ligands that specifically target EGFL7 may serve as 
promising molecular imaging tools to facilitate early diagnosis and monitor disease progression. 
 
 Here, we demonstrate the identification of novel EGFL7-targeting peptides through 
screening an OBOC peptide library. Using our previously established multiplex ‘beads on a 
bead’ approach (4), we describe a novel peptide, E7-p72 that specifically labeled human tumor 
and endothelial cells in an EGFL7-dependent manner. Incorporation of E7-p72 onto Cowpea 
mosaic virus (CPMV) nanoparticles also demonstrates the ability of this peptide to target 
nanoparticles to sites of high EGFL7 expression.  
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4.3 Methodology 
 
 
Cloning recombinant EGFL7  
 
EGFL7 cDNA was amplified by PCR (sense primer: 
(5’CACCATGAGGGGCTCTCAGGAGGTG3’ and anti-sense primer: 
5’CTACGAGTCTTTCTTGCAGGAGCAG3’) and cloned into the pENTR/TEV/D-TOPO vector 
(Invitrogen) according to the manual’s instruction. The TEV-EGFL7 region was cloned into 
pDEST20 plasmid (Invitrogen) by recombination and the recombinant bacmid DNA was isolated 
according to the Invitrogen manual’s instruction.  
 
 
Expression and purification of recombinant GST-EGFL7 
 
Recombinant baculovirus was generated from Spodoptera frugiperda, Sf21 cells that 
were transfected with 1µg of bacmid DNA using CellFECTIN tranfection reagent (Invitrogen). 
Plaque titration of the virus was performed according to the standard protocol described in the 
Invitrogen manual. Sf21 cells were seeded into a T175 cell culture flask with approximately 80% 
confluency. Upon cell attachment, the medium was removed and the cells were infected with the 
recombinant baculovirus at a multiplicity of infection (MOI) of 20 for 72 h at 27°C. The cell 
lysate was harvested in 0.1% NP40, and passed through a 1mLof glutathione-agarose resin. The 
column was then washed with 25 mL of wash buffer (150 mM, NaCl, 20 Tris–HCl, pH 7·9), and 
eluted with elution buffer supplemented with 20mM reduced glutathione. Elutions were collected 
in 1mL fractions and stored at 4oC. All eluted fractions were analyzed using SDS-PAGE and 
visualized by silver staining. 
 
 
Generation of EGFL7-magnetic screening beads 
 
All fractions containing EGFL7 recombinant protein were pooled together. 30 ug of anti-
GST antibody (Thermo Scientific) was mixed into the protein solution, and incubated with 370 
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mg of MagnaBind Protein A/G magnetic beads (Thermo Scientific) for 15 minutes at 4oC. After 
several washes with wash buffer, the conjugation of protein onto magnetic beads was analyzed 
by treatment of the screening beads with SDS loading buffer and heat, followed by western blot 
analysis using anti-EGFL7 polyclonal antibody (R&D Systems).  
 
 
Synthesis of Fluorescein-Labeled Peptides 
 
Fluorescein-labeled peptides were prepared following the general protocols outlines 
previously. Rink amide resin was used with Cys as the C-terminal amino acid, followed by the 
addition of Fmoc-Ahx-OH (amino-hexanoic acid) as a linker, followed by the amino acids for 
the sequence of either E7-p72 and E7-p74. Peptides were cleaved using cleavage cocktail 
comprised of TFA:EDT:TIS (95:2.5:2.5) and precipitated with cold t-butyl methyl ether. 
Peptides were dye-labeled using maleimide-fluorescein, purified by preparative HPLC (RP-C18) 
and characterized by ESI+-MS. 
 
 
Screening a OBOC library  
 
OBOC peptide library beads were washed extensively using 70% ethanol, distilled water 
and binding buffer (50mM Na2HPO4, 150mM NaCl, 2mM CaCl2, 0.2M L-Arginine, pH 7.4) 
before screening. First, a library enrichment step to remove potential false positive beads was 
performed by mixing the OBOC library with magnetic beads coated with the anti-GST antibody 
and GST protein complex for 1 h at 37 oC with constant shaking at 200 rpm. A strong 
neodymium magnet (K&J Magnetics, Pennsylvania, USA) was placed at the side of the vial for 
several minutes, and beads that did not respond to the magnet (enriched library) were transferred 
into another vial using a micropipette. The enriched library was washed five times with binding 
buffer. The second (EGFL7 specific) screen was performed by adding 50 µg of the EGFL7-
coated screening beads into the OBOC library under the conditions described above. A strong 
magnet was placed at the side of the vial, and the library was screened as described in (4). 
Positive hits were pooled and washed extensively with ethanol and water. A secondary cell-
based screen was performed using EGFL7-overexpressing HT1080-tdT human fibrosarcoma 
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cells, and EGFL7-low MDA-MB-435-GFP human breast cancer cells as described by Cho and 
collegues (4). Beads were visualized under an Olympus IX70 inverted fluorescent microscope, 
and beads that associated with the red (high EGFL7 expression) HT1080-tdT cells, but not the 
green (low EGFL7 expression) MDA-MB-435-GFP cells, were manually isolated using a 
micropipette.  Hit beads were collected, washed and peptides were sequenced on-bead using 
MALDI TOF MS/MS as described in (15) and (4). Isomeric isoleucine and leucine, and isobaric 
lysine and glutamine are indistinguishable by their mass to charge ratios and must be uniquely 
identified using alternate methods (29). 
 
 
SPR to identify high-affinity peptide for EGFL7  
 
Peptides were spotted onto SPR chip (GWC Technologies). Different concentrations (1 
nM, 20 nM, and 50 nM) of purified EGFL7 were flown over the chip for 10 mins. All procedures 
were done according to the SPRimager®II array instrument (GWC Technologies) protocol 
guide. An association curve was generated by plotting the percent change in reflectivity (%ΔR) 
at 10 mins against the concentration of EGFL7 (nM) using the GraphPad Prism software (version 
5).  
  
 
Evaluation of cell uptake of FITC-E7-p72 and FITC-E7-p74 peptides by microscopy 
 
Human HT-1080 fibrosarcoma cells or human umbilical vein endothelial cells 
(HUVECs) were detached using EDTA and resuspended in DMEM into microcentrifuge tubes. 
Cells were incubated with 3.3 µM of fluorescein-conjugated E7-p72, E7-p74 and control AGD 
peptide in suspension for 1 h at 37 oC. Blocking studies were conducted in the presence of 100x 
excess of non-fluoresceinated peptides. Cells were washed three times with PBS by 
centrifugation and seeded onto coverslips, washed and mounted. Images were captured using the 
Zeiss AxioImager Z1 microscope. The boundaries of cells were manually determined and the 
average fluorescein intensities within the selected region of interest were quantified using 
Volocity, version 4.0 (PerkinElmer, Massachusetts, USA). All statistics were performed using a 
one-way ANOVA and Tukey post hoc test.  
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siRNA knockdown of EGFL7 
 
EGFL7 siRNA (sense: 5'- UGAAGGAAGAAGUGCAGAGUU -3', antisense: 3`- 
UUACUUCCUUCUUCACGUCUC -5`) (Sigma, Canada) or scrambled siRNA (negative 
control) (sense: 5` GAAGTAACACCCGCACCTAUU 3`, antisense: 3`- 
UUCUUCAUUGUGGGCGUGGAU -5`) (Sigma, Canada) were used to transfect HT1080 cells. 
Cells were seeded onto a 6-well plate and transfected with either EGFL7 siRNA at a final 
concentration of 40 nM using INTEFERin transfection reagent (Polyplus transfection). After 48 
hrs, Western blot analysis of transfected cells was performed to confirm knockdown using the 
anti-EGFL7 polyclonal antibody (R&D systems).  
 
 
Evaluation of cell uptake of FITC-E7-p72 by flow cytometry 
 
HT1080 fibrosarcoma cells were stably transfected to overexpress EGFL7-v5 protein 
(HT1080-EGFL7). EGFL7 knockdown in HT1080 cells were achieved using siRNA (HT1080-
KD) as previously described. Regular HT1080, HT1080-EGFL7 (overexpressing) and HT1080-
KD cells were seeded onto separate wells in a 6-well tissue culture plate to approximately 80% 
confluency. The cells were incubated overnight in DMEM containing 10% fetal bovine serum 
and Pen/Strep at 37 oC with 5% CO2. The media in each well were removed and replaced with 
pre-warmed PBS. FITC-AGD (negative control) or FITC-E7-p72 peptide was added onto cells to 
a final concentration of 1 µM and incubated for 1 hour at 37 oC with 5% CO2. Cells were washed 
three times with PBS, fixed with 4% formaldehyde, and the uptake of FITC-labeled peptides 
were analyzed by flow cytometry using the COPAS flow cytometer (Union Biometrica). Data 
analysis was performed using FCS express (version 3).  
 
The evaluation of E7-p72 uptake by HUVECs using flow cytometry was performed using 
the same procedures. 
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Synthesis of CPMV-PEG-E7-p72 and evaluation of cell uptake of CPMV-PEG-E7-p72 by 
EA.hy926 endothelial cells using flow cytometry 
 
Propagation and purification of CPMV was performed using standard procedures 
described in (30). Alkyne was introduced into the peptide using the following procedure: Peptide 
synthesis was performed on Fmoc-Lys(aloc) functionalized Rink amide resin (0.1 mmol scale) 
using standard solid phase peptide synthesis (SPPS) chemistry. The Lys(aloc) was deprotected 
using phenylsilane (296 uL, 24 eq) and Pd(PPh3)4 (10 mg, 0.1 eq) in degassed DCM (2 mL) for 
10 min, rinsed with DCM, and repeated once. N3-(PEG)7-COOH (166 mg, 3 eq) was coupled 
overnight using HCTU (124 mg, 3 eq) and DIPEA (104 uL, 6 eq) in DMF (2 mL). The final 
Fmoc group was removed with 20% piperidine in DMF.  The peptide was cleaved from resin 
using 95:2.5:2.5 TFA:TIPS:H2O (2 mL) for 3 h.  The peptide was precipitated with cold methyl 
tert-butyl ether (MTBE), centrifuged, and the ether decanted.  The peptide was purified with 
preparative HPLC, and the fractions lyophilized to yield the peptide as a TFA salt.  
 
Multifunctional CPMV conjugates were synthesized according to the procedures 
described by Steinmetz at al. (6).  
 
Step 1: AF647 succinimidyl ester was dissolved in DMSO, the labels were used in a molar 
excess of 1000 to CPMV (2-3 mg mL-1), the reaction was carried out for 4-5 hrs at room 
temperature in the dark in a in PBS:DMSO mixture of 9:1. Samples were purified by 
ultrapelleting (Beckman 50.2 Ti rotor, 42000 rpm, 3 hrs, 4 °C). CPMV was re-suspended in PBS. 
 
Step 2: N-(4-Pentynoyloxy) succinimide (provided by Vu Hong, The Scripps Research Institute) 
was added in a molar excess of 2000:1 per CPMV nanoparticle. Reaction conditions were as 
described above, after overnight reaction samples were purified by ultrapelleting and re-
suspended in PBS and stored at 4 °C. 
 
Step 3: Covalent attachment of PEG and PEG-E7-p72 was achieved using optimized click 
chemistry protocols. To a buffered solution of CPMV-A647-alkyne (0.4 µM final concentration) 
azide-PEG-E7-p72 and azide-PEG-E7-p72 (150 µM) in DMSO, respectively, was added in a 
molar excess of 625:1 per CPMV. For coupling the following reagents were added: amino 
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guanidine (AMG, 5 mM), CuSO4:TBTA-OH in a molar ratio of 1:5 (500 µM CuSO4, 2.5 mM 
TBTA-OH), and sodium ascorbate (5 mM). The ligand TBTA-OH (trishydroxypropyl triazole) 
was provided by Vu Hong (TSRI). The reaction mixture was incubated at room temperature for 
60 min on a shaker prior to purification by ultrapelleting (as described above).  
 
CPMV-PEG (control) and CPMV-PEG-E7-p72 were stored in PBS at 4 oC before further use. 
Flow cytometry to analyze the cell uptake of CPMV-PEG-E7-p72 and control CPMV-PEG (1 
µg) was performed. EGFL7 knockdown in EA.hy926 cells was achieved using siRNA (EA.hy-
KD) using jetPRIME transfection reagent (Polyplus Transfection). After 48 hrs, regular 
EA.hy926 and EA.hy-KD cells were seeded onto separate wells in a 6-well tissue culture plate to 
approximately 80% confluency. EA.hy921 cells were incubated with CPMV-PEG (control) or 
CPMV-E7p72 at 37oC for 3 hours. Cells were washed three times with PBS, and then detached 
using 2.5 mM EDTA, and resuspended in flow buffer (PBS with 2mM EDTA, 2% FBS and 
0.05% sodium azide). Data analysis was performed using FCS express (version 3). 
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4.4 Results 
 
 
A high-throughput approach to screen OBOC library for EGFL7-binding ligands.  
 
We previously described the development of a multiplex ‘beads on a bead’ approach to 
exploit the tendency of small magnetic screening beads (2 µm diameter) coated with a target 
protein to reversibly interact with much larger TentaGel beads (90 µm diameter) that comprise 
random OBOC combinatorial libraries (4). Purified recombinant GST-EGFL7 (target protein) 
was adsorbed to 2 µm protein A/G-coated magnetic beads via the anti-GST antibody (Figure 
4.1a). It was expected that upon mixing of magnetic screening beads containing the target protein 
with an OBOC library, the screening beads would coat the TentaGel beads in an affinity-
dependent manner (Figure 4.1a). Ligands with the highest affinity for the target protein could 
then be isolated by placement of a magnet at the side of the vial, as they would pool towards the 
magnet (Figure 4.1b). The affinity of hit peptides for the target protein could then be validated 
on-bead using live cells prior to sequencing using mass spectrometry technique as we have 
previously described (4, 15). HT1080-tdT cells (red) that overexpress EGFL7 (EGFL7 positive) 
and regular MDA-MB-435-GFP cells (green) (EGFL7 negative) were used in this secondary 
screen to verify the interaction of hit peptides with EGFL7 on living cells (Figure 4.1c). Hit 
beads that associated strongly with red, but not green cells were isolated either through manual 
techniques with a micropipette, or by automated sorting using the COPAS large particle flow 
cytometer. 
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Figure 4.1. A high-throughput strategy used to screen an OBOC peptide library against 
recombinant EGFL7 protein. (a) Schematic representation of the beads on a bead approach. 
Purified recombinant GST-EGFL7 protein was bound onto Protein A/G-coated magnetic beads 
via an anti-GST antibody, and mixed with a library of TentaGel beads displaying random 8-
amino acid peptides. (b) TentaGel beads displaying high affinity peptides that strongly retained 
magnetic beads on their surfaces were isolated using a magnet. (c) Schematic representation of a 
secondary cell-based screen using EGFL7-overexpressing HT1080-tdT cells and EGFL7-low 
HT1080-GFP cells. Positive hit beads were isolated using the COPAS Biosort instrument (Union 
Biometrica), and peptides were sequenced on-bead using MALDI TOF MS/MS.  
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The identification of novel EGFL7-targeting ligands. 
 
First, recombinant EGFL7 was purified using the baculovirus expression system as 
described in the methodology section. Silver staining of SDS-PAGE gels showed the purification 
of GST-EGFL7 from cell extract to its purified state (Figure 4.2a). The purification of EGFL7 
was confirmed by analyzing the eluted fractions by western blot analysis (Figure 4.2b). Next, in 
order to generate EGFL7 magnetic screening beads, purified EGFL7 were conjugated onto 
Protein A/G magnetic beads via an anti-GST antibody. Western blot confirmed that purified 
EGFL7 was successfully conjugated onto magnetic particles (Figure 4.2c). 
  
To isolate novel peptides targeting EGFL7, 1 g of an octapeptide OBOC library was 
screened using 2 µm EGFL7-coated magnetic beads. The initial magnetic separation step 
isolated roughly 500 hits, which were subsequently refined by screening them against living cells 
and sorting. The expression of EGFL7 in EGFL7 over-expressing (EGFL7 positive) HT1080-tdT 
fibrosarcoma cells and EGFL7-low (EGFL7 negative) MDA-MB-435-GFP breast cancer cells 
was confirmed by Western blot (Figure 4.2d). In total, 16 library beads that bound to ‘EGFL7 
positive’ cells, but not ‘EGFL7 negative‘ cells were isolated and sequenced using a previously 
described mass spectrometry approach (15). This led to the successful identification of 8 unique 
peptide sequences. Four of these hit peptides; E7-p72, E7-p73, E7-p74 and E7-p75 were 
synthesized and purified based of our confidence in the MALDI deconvolution. The sequences 
of these peptides are displayed in Table 4.1. 
 
 
Table 4.1. Sequences of isolated hit peptides. 
 
Peptide Sequences 
E7-p72 HYMFLLGH 
E7-p73 SQSSMYPS 
E7-p74 WYKLHPTM 
E7-p75 EWELHAEE 
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Figure 4.2. The identification of novel EGFL7-binding ligands through screening an OBOC 
library. (a) Silver-stained gel showing the purification of recombinant GST-EGFL7 protein 
(left). The eluted fractions were subjected to western blot analysis using a polyclonal anti-
EGFL7 antibody (right). (b) Western blot analysis confirming the conjugation of purified EGFL7 
protein onto the magnetic beads. (c) A secondary cell-based screening approach to identify 
peptides with high affinity for EGFL7 displayed on cell surface. Western blot analysis using a 
polyclonal anti-EGFL7 antibody shows negligible EGFL7 level in MDA435-GFP cells and high 
EGFL7 level in HT1080-tdT cells that overexpress EGFL7 (right). Fluorescence microscopic 
image of an example hit bead that strongly associated with HT1080-tdT cells that overexpress 
EGFL7 (red), but have very little interaction with MDA435-GFP cells (green) that do not 
express EGFL7.  
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The characterization of high-binding ligands for EGFL7, E7-p72 and E7-p74  
 
The four peptides listed in Table 4.1 were synthesized and further characterized. The 
interaction of these peptides with purified EGFL7 was simultaneously monitored through surface 
plasmon resonance (SPR) imaging (GWC Technologies) (Figure 4.3a). A peptide array was 
prepared by conjugation of each peptide onto individual gold-coated spots on a SPR chip (GWC 
Technologies), followed by incubation with purified EGFL7. Two (E7-p72 and E7-p74) of the 
four hit peptides were observed to bind most strongly to EGFL7 in a concentration-dependent 
manner (Figure 4.3a). E7-p72 and E7-p74 generated the steepest slopes, indicating that EGFL7 
bound to these two peptides at the highest rates (Figure 4.3a). The lines produced by E7-p73 and 
E7-p75 were not significantly different from that of control (Figure 4.3a). Through monitoring 
the change in reflectivity over time as EGFL7 associates with or dissociates from the spots, the 
KD value for E7-p72 and E7-p74 was calculated to be 13.2 nM and 14.3 nM, respectively 
(Supplementary Figure 4.1). E7-p72 and E7-p74 were conjugated with a fluorescein dye for 
further uptake analysis. The chemical structures of FITC-E7-p72 and FITC-E7-p74 are as shown 
in Figure 4.3b. 
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Figure 4.3. E7-p72 and E7-p74 have highest affinity for EGFL7. (a) Association curves 
generated from the interaction of hit peptides with purified recombinant EGFL7 using the 
SPRimager II (GWC Technologies). Association curves were produced by subjecting peptides 
immobilized onto the SPR chip with different concentrations of EGFL7 (1 nM, 20 nM, and 50 
nM). At t = 600s (10 mins), the percent change in reflectivity (%ΔR) was plotted against the 
EGFL7 concentration (nM) using the GraphPad Prism, version 5.0. The slope (m) of each line 
indicates the rate of EGFL7 association with the peptide. (b) Chemical structure of fluorescein-
labeled E7-p72 and E7-p74 (right).  
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FITC-conjugated E7-p72, but not E7-p74 peptide is taken up by HT1080 fibrosarcoma 
cells in an EGFL7-dependent manner 
 
E7-p72 and E7-p74 were conjugated with a fluorescent dye (fluorescein) and their ability 
to selectively bind EGFL7 expressing HT1080 fibrosarcoma cells were assessed using 
fluorescence microscopy and flow cytometry. The uptake of FITC-E7-p72 by regular HT1080 
cells was 6 times higher than that of FITC-AGD (control peptide) (Figure 4.4a and b).  Blocking 
with 100 molar excess of non-fluoresceinated E7-p72 peptide significantly reduced the binding 
and uptake FITC-E7-p72 (Figure 4.4b). No significant uptake of FITC-E7-p74 by HT1080 cells 
was observed. The uptake of FITC-E7-p72 by HT1080 cells that overexpress EGFL7 (HT-
EGFL7) was approximately 2 times higher than that by regular HT1080 cells (Figure 4.4c and 
d).  
 
Similarly, flow cytometry analysis confirms the affinity of FITC-E7-p72 with HT1080 
cells in an EGFL7 dependent manner. The expression of EGFL7 protein in regular HT1080, 
EGFL7-knockdown HT1080 (HT1080-KD) and EGFL7-overexpressing HT1080 (HT1080-
EGFL7) cells was verified by western blot (Figure 4.5a). The fluorescein signal intensity 
observed in regular HT1080 cells was significantly higher than that in untreated cells (Figure 
4.5b). Knockdown of EGFL7 using siRNA significantly reduced the uptake FITC-E7-p72 by 
cells, while overexpression of EGFL7 increased the uptake of FITC-E7-p72 by more than 4 
times (Figure 4.5b). 
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Figure 4.4. FITC-E7-p72, but not FITC-E7-p74 peptide is taken up by HT1080 
fibrosarcoma cells in an EGFL7-dependent manner as evaluated by microscopy. (a) 
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Fluorescence images showing the uptake of FITC-conjugated E7-p72, E7-p74 and AGD 
(negative control) (final concentration of 3.3 µM) by HT1080 cells. Left panels: FITC signal 
from peptide uptake (green). Right panels: merged images of brightfield image, nuclei staining 
(red) and FITC-conjugated peptide (green). Blocking study was conducted by adding 100x 
excess of non-fluoresceinated peptides. Scale bar, 10 µm. (b) Bar graph showing the mean FITC 
intensity of cells from each group (as in (a)). Measurements of peptide uptake were performed by 
selection of the perimeter of each cell, and then obtaining the mean FITC intensity within 
selected regions using the Volocity software (Improvision). The uptake of FITC-E7-p72, but not 
FITC-E7-p74 was significantly higher than that of control AGD (n = 30, p < 0.001). The uptake 
of FITC-E7-p72 was significantly reduced in the presence of 100x excess non-fluoresceinated 
E7-p72 peptide (n = 30, p < 0.001). (c) Fluorescence images showing the uptake of FITC-
conjugated E7-p72 (final concentration of 3.3 µM) by HT1080 cells and HT1080-EGFL7 
overexpressing cells. Left panels: FITC signal (green). Right panels: merged images of 
brightfield image, nuclei staining (red) and FITC-conjugated peptide (green). Bar graph showing 
the mean FITC intensity of cells from each group (from (c)). Peptide uptake was quantified as 
described above. The uptake of FITC-E7-p72 was significantly higher in HT1080-EGFL7 
overexpressing cells compared to regular HT1080 cells (n = 30, p < 0.001). Scale bar, 10 µm. (d) 
All statistics were performed using a one-way ANOVA and Tukey post hoc test.  
  
  
95 
 
 
Figure 4.5. FITC-E7-p72 is taken up by HT1080 fibrosarcoma cells in an EGFL7-
dependent manner as evaluated by flow cytometry. (a) Western blot analysis showing the 
knockdown of EGFL7 by siRNA and overexpression of EGFL7 in HT1080 cells using the 
EGFL7 polyclonal antibody (R&D Systems). (b) Bar graph showing the uptake of FITC-E7-p72 
by regular HT1080, HT1080-KD (EGFL7 knockdown) or HT1080-EGFL7 (overexpressing) 
cells. Uptake of FITC-E7-p72 was analyzed by flow cytometry using the COPAS flow cytometer 
(Union Biometrica). All statistics were performed using a one-way ANOVA and tukey post hoc 
test.  
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FITC-conjugated E7-p72 is taken up by HUVECs in an EGFL7-dependent manner 
 
As our main objective is to develop E7-p72 as an EGFL7-targeting agent to image 
angiogenic blood vessels, we sought to study its uptake by human endothelial cells. Flow 
cytometry analysis shows the specific uptake of FITC-labeled E7-p72 by human umbilical vein 
endothelial cells (HUVECs) in an EGFL7 dependent manner. First, the expression of EGFL7 
protein in regular HUVECs and EGFL7-knockdown HUVECs (HUVECs-KD) was confirmed by 
western blot (Figure 4.6a). Approximately 41.2% of cells displayed fluorescence intensity above 
background signal upon treatment with E7-p72 (Figure 4.6b). Knockdown of EGFL7 in 
HUVECs decreased the number of cells with signal intensity above background level to 20.9% 
(Figure 4.6b). The average fluorescein signal observed in HUVECs treated with E7-p72 was 
significantly higher than that in untreated cells (Figure 4.6c). Knockdown of EGFL7 in 
HUVECs-KD significantly reduced the uptake FITC-E7-p72 by cells by almost 50% (Figure 
4.6c). 
 
Taken together, these data suggest that FITC-E7-p72, but not E7-p74 has a high binding 
affinity for EGFL7 and specifically targets cells expressing EGFL7. 
 
  
97 
 
 
 
Figure 4.6. FITC-E7-p72 is taken up by HUVECs in an EGFL7-dependent manner as 
evaluated by flow cytometry. (a) Western blot analysis showing EGFL7 expression and EGFL7 
knockdown (by siRNA) in HUVECs using the EGFL7 polyclonal antibody (R&D Systems). (b) 
Dot plot showing the uptake of FITC-E7-p72 by HUVECs or HUVECs-KD (EGFL7 
knockdown). Flow cytometry analysis was performed using the COPAS flow cytometer (Union 
Biometrica) and the plot was generated using FCS express (version 3). Fluorescence signal 
higher than the major population of untreated cells were gated for analysis. (c) Bar graph 
showing the uptake of FITC-E7-p72 by HUVECs or HUVECs-KD. All statistics were performed 
using a one-way ANOVA and tukey post hoc test.  
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CPMV-PEG-E7-p72 nanoparticles are taken up by human endothelial cells in an EGFL7-
dependent manner 
 
We then, sought to evaluate the ability of E7-p72 to specifically target fluorescent 
nanoparticle (conjugated with Alexa Fluor 647 near-infrared dyes and PEG to eliminate non-
specific binding) to EGFL7-expressing human endothelial cells. Flow cytometry analysis reveals 
that CPMV-PEG-E7-p72 nanoparticles specifically bind or are internalized by human EA.hy926 
endothelial cells in an EGFL7 dependent manner. The expression of EGFL7 protein in regular 
EA.hy926 and EA.hy-KD (EGFL7 knockdown) was confirmed by western blot (Figure 4.7a). 
The mean geometric mean fluorescence intensity of cells treated with CPMV-PEG-E7-p72 
(43.4) is much higher than that seen in cells treated with control nanoparticles, CPMV-PEG 
(14.8) (Figure 4.7b). Knockdown of EGFL7 in EA.hy926 (EA.hy-KD) decreased the mean 
geometric mean fluorescence intensity to 34.6 (Figure 4.7b).  
 
These data suggest that E7-p72 peptide can be used to direct nanoparticles to sites where 
EGFL7 expression is high. We intend to further evaluate the ability of CPMV-PEG-E7-p72 to 
target sites of high EGFL7 expression in vivo in a mouse xenograft model of prostate cancer. 
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Figure 4.7. CPMV-PEG-E7-p72 is taken up by EA.hy926 human endothelial cells in an 
EGFL7-dependent manner. (a) Western blot analysis showing the EGFL7 expression and 
EGFL7 knockdown (by siRNA) in EA.hy926 cells using the EGFL7 polyclonal antibody (R&D 
Systems). (b) Histogram indicating the uptake of CPMV-PEG-E7-p72 and CPMV-PEG (control) 
by EA.hy926 or EA.hy-KD (EGFL7 knockdown) cells. The mean fluorescence intensity of each 
group is indicated in this plot. 
 
  
100 
 
Characterization of E7-p72 and E7-p72(Daa) in preparation for in vivo studies using 
human prostate cancer xenograft mouse model  
 
In preparation for in vivo studies, we first examined if E7-p72 can recognize mouse 
EGFL7 and target mouse cells. We show that the uptake of FITC-E7-p72 by mouse B16F10 
mouse melanoma cells was much higher than that of FITC-AGD (control peptide) 
(Supplementary figure 4.2a). We intend to investigate the ability of E7-p72 to target mouse 
EGFL7 more rigorously by performing further uptake studies that incorporates cells with 
differential expression of EGFL7. 
 
The half-life of E7-p72 in serum was determined to be approximately 8 minutes 
(Supplementary Figure 4.2a). This result prompted us to pursue the development a more stable 
peptide alternatives that incorporates D-amino acid. Alanine scan studies through enzyme-linked 
immunosorbent assay (ELISA) show that only the Phe residue in the middle of the peptide was 
crucial for E7-p72 binding to EGFL7, and that mutation of the Phe to Ala residue decreased the 
binding of E7-p72 to EGFL7 to a level observed in the negative control peptide (Supplementary 
Figure 4.2b). Based on our observation that the flanking His residues were not essential for 
binding to EGFL7, we substituted both L-His (H) in E7-p72 with D-histidines (h) to generate a 
2nd generation peptide, E7-p72(Daa). We have demonstrated that E7-p72(Daa) has an improved 
half life in both human serum (~2.5 hours) and mouse serum (~1 hour) (Supplementary Figure 
4.2c). However, further investigation is required to test the efficacy of this peptide in targeting 
EGFL7 in vitro and in vivo.  
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4.5 Discussion and conclusion 
 
  Here, we report the discovery of novel EGFL7 affinity ligands from screening an OBOC 
library using our previously developed ‘beads on a bead’ strategy (4). While we have described 
the utility of the biotin-streptavidin interaction to directly conjugate and display the target protein 
onto magnetic beads in an unbiased manner, our initial attempts to biotinylate EGFL7 has been 
unsuccessful. We presume that this issue may be related to the folding pattern of EGFL7, and 
that it is possible that EGFL7 does not contain any exposed lysine residues on its surface that are 
available for biotinylation through the N-hydroxysuccinimide ester reaction. As an alternative 
method, an anti-GST antibody has been used to conjugate recombinant GST-EGFL7 protein onto 
magnetic beads. Since only the GST epitope was directly linked onto the magnetic bead, we 
presume that this conjugation did not mask any sites on EGFL7, and that all surfaces of EGFL7 
are equally exposed to the ligands on the library beads. 
 
 To eliminate false positives, that is promoted by the utility of several extrinsic molecules 
(ie. magnetic beads, anti-GST antibody and GST protein), we have performed a library 
enrichment step by first removing all the library beads that interacted with magnetic beads coated 
with purified GST protein via the anti-GST antibody. Magnetic beads containing EGFL7 are 
then used to screen the enriched library. To further reduce the number of false positives, an on-
bead cell-based assay has been performed to verify affinity of isolated ligands for EGFL7 that 
are expressed in their native conformation on the cell surface. This step can significantly 
narrowed down the final number of hits for sequencing analysis, and increased the prospect of 
attaining high affinity ligands that can target EGFL7 on cell surface. 
 
From the screen, we have isolated four peptide ligands of EGFL7, with no conserved 
motif observed between peptides. E7-p72 and E7-p74 peptides have exceptional affinity for 
purified EGFL7 protein, although only E7-p72 binds to and is taken up by cancer cells and 
endothelial cells in an EGFL7-dependent manner. No conserved motif is observed between 
peptides, and the E7-p72 sequence is not found in any human proteins. However, a similar motif 
is detected in sphingolipid delta(4)-desaturase DES1 and DES2 (HYMFLKGH), as well as in G-
protein coupled receptor 146 (HYLILLGH). These findings may suggest that these proteins can 
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be potential ligands of EGFL7, and can therefore, provide important information and give us new 
insights into the mechanisms by which EGFL7 function. 
 
 Here, we describe the synthesis and application of E7-p72 as a first line peptide for 
molecular imaging of EGFL7 expressing cells. Although this peptide is successful at targeting 
cancer cells and endothelial cells in an EGFL7 dependent manner, this peptide is composed of L-
amino acids, and with a very short half-life of 8 minutes in human serum. While this may not be 
an issue for applications in vitro, the stability of E7-p72 needs to be optimized prior to utilization 
in vivo. Nonetheless, E7-p72 can serve as a parent peptide for further development of novel 
EGFL7 ligands with improved stability and greater targeting efficacy. We are currently in the 
process of developing and characterizing a 2nd generation peptide, E7-p72(Daa) that incorporates 
flanking D-histidines. Although we have demonstrated that E7-p72(Daa)  has an improved half 
life in both human and mouse serum, further investigation is required to test the efficacy of this 
peptide in targeting EGFL7 in vitro and in vivo.  
 
 While this novel peptide effectively targets EGFL7-expressing cancer cells and 
endothelial cells in vitro, we are in the process of evaluating the ability of E7-p72 to target 
fluorescent nanoparticles to prostate tumors and/or angiogenic sprouts in mice in vivo. As our 
preliminary results indicate that the uptake of E7-p72 by mouse melanomal cells is significantly 
higher than that of control peptide, combine with our knowledge that the mouse EGFL7 
sequence is highly homologous to human EGFL7 (31), we are optimistic that E7-p72 can be used 
to target nanoparticles to EGFL7-expressing tumors and angiogenic vessels.  
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5.1 Abstract 
 
Angiogenesis is a promising therapeutic target in cancers, supported by a comprehensive 
analysis of tumour vasculature in prostate cancers that reported that men with the most 
irregularly shaped vessels are 17.1 times more likely to develop lethal disease. These vessels 
specifically express a recently identified 30 kDa secreted protein called epidermal growth factor-
like 7 (EGFL7). Here, we describe the identification and characterization of novel EGFL7-
derived peptides that can inhibit angiogenesis through interfering with the function of EGFL7. 
We found two motifs from the EGFL7 sequence that are highly conserved across multiple 
species, but are not present in its paralog, the EGFL8 protein. We demonstrate that E7-C13 
inhibited the morphogenesis of endothelial cells in vitro and also reduced the level of 
angiogenesis induced by tumor cells in vivo in both the avian embryo and mouse models. Efforts 
to evaluate the mechanism of action and the efficacy of these peptides in treating tumours in 
animal models are currently underway. These peptides could provide a basis for a new 
generation of therapeutic agents for locally advanced prostate cancers.
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5.2 Introduction 
 
Angiogenesis is a process where new capillaries are formed from existing blood vessels, 
and has been implicated in a variety of pathological human diseases, including cancer and 
diabetic retinopathy. The importance of angiogenesis in the progression of tumorigenesis is well 
recognized and established (reviewed in (1)). The angiogeneic switch is activated during the 
early stages of tumor development, whereby tumors secrete diffusible angiogenic inducers to 
signal quiescent vasculature to undergo capillary sprouting. Tumor cells express various 
angiogenic factors, including vascular endothelial growth factor (VEGF) (2), tumour necrosis 
factor alpha (TNF-α) (3), and transforming growth factor-alpha (TGF-α) (4), leading to 
increased angiogenesis. Receptor tyrosine kinases (RTKs) are cell surface membrane proteins 
that mediate the transmission of extracellular cues from signaling molecules (such as growth 
factors, cytokines or hormones) into the intracellular environment, thereby modulating processes 
such as angiogenesis (reviewed in (5)). Activation of RTKs through binding of a ligand on the 
extracellular domain leads to receptor dimerization and auto-phosphorylation of the receptor, 
resulting in a series of signaling transduction which ultimately governs several important cellular 
processes including cell migration, cell proliferation and angiogenesis (reviewed (6)).  
 
A convergent perspective regarding angiogenic activators is that negative regulators, 
known as angiogenesis inhibitors, play an equally important role in controlling the switch. The 
significance of angiogenesis inhibitors were first introduced by Bouck and colleagues who 
demonstrated that tumorigenic cell lines contained much lower levels of inhibitor, which was 
later identified as a truncated version trombospondin-1 (TSP-1) (7, 8). Several anti-angiogenic 
agents have been developed to target different stages involved in angiogenesis (reviewed in (9)). 
Advancement in screening technologies continues to facilitate the discovery of novel anti-
angiogenesis agents (10, 11).  
 
Several anti-angiogenesis compounds have been developed, and have either been 
approved by the FDA (such as Avastin (12), Sutent (13) and Nexavar (14)) or are still currently 
undergoing clinical trials (such as TNP-470 (15), aflibercept (16), cediranib (17) and pazopanib 
(18). Nonetheless, despite their ability to effectively treat certain cancers, these drugs each have 
their own limitations. For example, although Avastin has been demonstrated to significantly 
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increase the progression-free survival and overall survival of patients with metastatic colorectal 
cancer (19), it did not provide any benefit to the survival of patients with metastatic breast cancer 
(20). In addition, it has also been shown that most tumors develop resistance mechanisms to anti-
angiogenic drugs (21, 22), most likely as a consequence of long-term administration. As 
angiogenesis is regulated by several different signaling pathway, blocking a single pathway can 
lead to resistance when tumors develop an alternative angiogenesis mechanism (reviewed in 
(23)). Targeting multiple pathways of angiogenesis may overcome or delay resistance, 
highlighting the importance of combining drug therapies in the clinic. Hence, there remains a 
great necessity to identify new targets associated with angiogenesis and the development of 
novel pre-clinical anti-angiogenic agents.  
 
Epidermal growth factor-like domain 7 (EGFL7) is a ~30 kDa protein that consists of an 
amino-terminal signal peptide domain, an EMI domain and an EGF-domain (containing 2 EGF 
repeats) (24). EGFL7 is a secreted protein that is predominantly associated with the extracellular 
matrix (ECM) upon secretion (25). The EGFL7 protein has a paralogue, known as EGFL8 (25). 
EGFL7 is expressed mainly in the endothelium, with high levels observed in endothelial cells 
during embryogenesis, as well as physiological and pathological angiogenesis. Recent studies 
show that EGFL7 regulates the development of blood vessels by creating a permissive 
environment for endothelial cell migration and assembly sprouting of endothelial sprouts (25, 
26). EGFL7 is a chemoattactant for endothelial cells, and also promotes cell adhesion (25, 27). 
EGFL7 has been implicated to modulate angiogenesis through inhibition of the Notch signalling 
pathway (28, 29). In vivo study in zebrafish demonstrates that EGFL7 knockdown impairs 
tubulogenesis through a mechanism that is independent of VEGF signaling (25). Overexpression 
of EGFL7 in mice results in defective vasculature remodeling, with embryos exhibiting partial 
lethality and hemorrhaging (29). Altogether, these studies demonstrate that EGFL7 plays a 
crucial role in vasculature patterning, remodeling and stabilization, highlighting the importance 
of EGFL7 for angiogenesis.   
 
Recent preclinical studies show that combining anti-VEGF therapy and humanized anti-
human EGFL7 monoclonal antibodies led to additional inhibitory effect of tumor growth in 
human cancer xenograft mouse models when compared to anti-VEGF therapy (Avastin) alone 
(http://ip.com/patapp/US20110200602). Clinical trials (by Genentech) are currently underway to 
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evaluate the efficacy of combined anti-EGFL7 and Avastin therapy on inhibiting tumor growth 
and reducing tumor vascular function (http://www.gene.com/gene/pipeline/status/oncology/anti-
egfl7).  
 
Peptide based probes are attractive tools for developing therapeutic agents due to their 
size, stability, solubility, improved pharmacokinetics and lack of immunogenicity (30). The 
protein sequence of endogenous angiogenesis inducers or inhibitors contains vital information 
for designing new anti-angiogenic peptides as therapeutic drugs, as conserved domains or critical 
amino acid residues are critical for their function (reviewed in (31)). We therefore sought to 
identify and design novel bioactive anti-angiogenic peptides derived from endogenous human 
EGFL7 protein. To do this, we performed a Basic Local Alignment Search Tool (BLAST) search 
to identify regions of local similarity between the EGFL7 sequences from various species, and 
discovered the E7-C13. Herein, we report a first line peptide against EGFL7, E7-C13, which 
possesses anti-angiogenesis activity both in vitro and in vivo. This peptide is a promising 
candidate for developing novel anti-angiogenic agents. 
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5.3 Methodology 
 
Synthesis of E7-C13 (Ac-GSLLVHSFQQLG-NH2) 
 
The unsubstituted rink-amide resin was treated with 20% pipperdine in DMF to provide a free 
amine polymeric support ready for coupling. Fmoc-Gly-OH was then coupled to the support 
using HBTU (3 eq.) as coupling agent in DMF in presence of DIPEA (6 eq.). The removal of 
Fmoc protective group could be achieved in basic conditions using 20% piperidine solution in 
DMF. The elongation of the peptide has been carried out in a sequentially manner by alternating 
deprotection of Fmoc group and coupling of the amino acid. Each individual 
deprotection/coupling reaction was monitored for completeness prior to the next 
deprotection/coupling by ninhydrin test. Finally, acetylation of the N-terminal was performed on 
the solid support using anhydride acetic (Ac2O), Hunig base with DCM as solvent. 
The peptide was cleaved and deprotected from the polymeric support using a freshly prepared 
TFA cocktail containing phenol, EDT and distilled water as scavengers at room temperature. 
The peptide was precipitated from the acidic cocktail upon addition of tert-butyl methyl ether 
and was collected by centrifugation. Lyophilisation led to the crude peptide powder which was 
purified by reverse phase HPLC on a SunFire Prep column (3 x 150 mm, Waters) under linear 
gradient elution with eluent A consisted of 0.1% TFA in water while eluent B consisted of 0.1% 
TFA in acetonitrile. The elution was monitored at 220 nm at a flow rate of 20 mL/min. The 
purity of the final peptide product was checked by analytical HPLC performed on a reverse 
phase SunFire analytical column (4.6 x 150 mm, Waters) using the mobile phases described 
above, using a solvent gradient of 10% - 90% B over 15 min with a flow rate of 2 mL/min and 
detection at 220 nm.  
The scrambled peptide (control) (Ac-QVLSGLHQGLFS-NH2) was synthesized and purified 
using the same method. 
 
 
Synthesis of control Flag peptide (H-CSGDYKDDDDK-OH) 
 
The peptide was synthesized using the standard Fmoc chemistry on a multistep automated 
synthesizer (Appec) at 0.1 mmol scale with Fmoc-Lys(Boc)-Wang resin as polymeric support 
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under nitrogen atmosphere. The Fmoc-amino acids were used with the following side-chain 
protections: Asp-(OtBu), Lys-(Boc), Ser-(tBu), Tyr-(OtBu), Lys(Boc) and Cys-(tBu). Acidic 
treatment of the peptidyl-resin allowed the cleavage and deprotection of the peptide using TFA 
with the following scavengers: phenol, EDT, thioanisole and distilled water. The peptide product 
was purified and the purity checked using same conditions as described above.  
 
 
Purification of recombinant EGFL7-myc protein 
 
Recombinant baculovirus was generated from Spodoptera frugiperda, Sf21 cells that were 
transfected with 1µg of bacmid DNA using CellFECTIN tranfection reagent (Invitrogen). Plaque 
titration of the virus was performed according to the standard protocol described in the 
Invitrogen manual. Sf9 cells were cultured in a shaking incubator in SFM-900 II media 
(Invitrogen). Cells were infected with the recombinant baculovirus at a multiplicity of infection 
(MOI) of 20 for 72 hrs at 27°C. After 72 hrs, cells were lysed in lysis buffer (150 mM NaCl, 20 
mM sodium phosphate, 0.1% NP40, pH 7.4), and the lysate was collected after centrifugation. 
Supernatant from myc hybridoma cells were added into the lysate, and the mixture was 
incubated on ice for 10 minutes. Protein A/G agarose (Thermo Scientific) were washed with 
lysis buffer, added into the mixture and incubated overnight on a rocker at 4°C. Resin was 
collected by centrifugation, washed three times with lysis buffer, and eluted in 250 µL of elution 
buffer (300 mM NaCl, 50 mM Na2HPO4, 200 mM L-arginine, 2 mM CaCl2, pH 4). 250 µL of 
neutralizing buffer (50 mM sodium phosphate, 200 mM L-arginine, 2 mM CaCl2, pH 8) was 
added to each elution, and protein was stored at 4°C before use. All eluted fractions were 
analyzed by SDS-PAGE and visualized by Coomassie or silver staining. 
 
 
 
Surface plasmon resonance (SPR) study to establish the binding affinity of E7-C13 to 
purified EGFL7 protein 
 
E7-C13 and control peptide were spotted onto SPR chip (GWC Technologies). Different 
concentrations (1 nM, 20 nM, 50 nM and 100 nM) of purified EGFL7 were inserted into the SPR 
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instrument and allowed to come into contact with the chip for 10 mins. All procedures were done 
according to the SPRimager®II array instrument (GWC Technologies) manufacturer’s guide. 
The percent change in reflectivity (%R) at 10 mins was plotted against the concentration of 
EGFL7 (nM) to generate an association curve using the GraphPad Prism software (version 5).  
 
 
Endothelial morphogenesis/angiogenesis assay 
 
A 96-well plate was coated with 50 µL per well of Matrigel. After the Matrigel solidified, 
approximately 2000 human umbilical vein endothelial cells (HUVECs) were seeded onto the 
surface of the polymerized Matrigel. VEGF (10 ng/ml) and bFGF (10 ng/ml) were added into 
each well as the angiogenic stimulus. Flag or E7C13 peptide was introduced at a concentration of 
200 µM and cells were incubated at 37°C in 5% CO2 for 6 hours. Cells were then visualized 
under an inverted microscope and endothelial tube formation was quantified by counting the 
number of branch points from each well (n = 3). All statistics were performed using a one-way 
ANOVA and Tukey post hoc test. 
 
 
On-plant CAM In vivo angiogenesis assay 
 
Avian embryos were cultured ex ovo according to the procedures described in Zijlstra and 
Lewis (32, 33). Collagen containing on-plants were prepared using HT1080 cells as positive 
angiogenic stimuli and transferred to the CAM of day 9 embryos as per Zijlstra and Lewis (32, 
33). The embryos were allowed to incubate undisturbed in a humidiﬁed incubator for 3 days, and 
the on-plants were imaged under the Lumar stereomicroscope (Zeiss Canada, Toronto, Canada). 
The on-plants were scored as illustrated by Zijlstra and Lewis (32), and the angiogenic index was 
determined. 
Directed in vivo angiogenesis assay (DIVAA) 
 
A DIVAA kit was used to assess angiogenesis in 7 week old female Nude mice (Crl:NU- 
Foxn1nu; Charles River), as per the manufacturer’s recommended protocol (Trevigen, 
Gaithersburg, MD). Briefly, angioreactor tubes were filled with basement membrane extract 
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(BME), BME+ 50,000 HT1080 cells, or BME+ 50,000 HT1080 cells transfected with EGFL7, 
and inserted subcutaneously into mice. After 10 days, mice were sacrificed, angioreactors were 
removed, and angioreactor contents were transferred into a centrifuge tube. Endothelial cells 
were labelled overnight in a FITC-Lectin solution, and fluorescence was quantified using a plate 
reader. All experiments involving animals were approved by the Animal Use Subcommittee at 
the University of Western Ontario (Protocol No. 2008-101). 
 
 
siRNA knockdown of EGFL7 
 
EGFL7 siRNA (EGFL7-si) (sense: 5`- UGAAGGAAGAAGUGCAGAGUU -3`, 
antisense: 3`- UUACUUCCUUCUUCACGUCUC -5`) (Sigma, Canada) or scrambled siRNA 
(negative control) (sense: 5` GAAGTAACACCCGCACCTAUU 3`, antisense: 3`- 
UUCUUCAUUGUGGGCGUGGAU -5`) (Sigma, Canada) were used to transfect HUVECs. 
HUVECs were seeded onto a 6-well plate and transfected with either EGFL7 siRNA at a final 
concentration of 40 nM using INTEFERin transfection reagent (Polyplus transfection). After 48 
hrs, Western blot analysis of transfected cells was performed to confirm knockdown using the 
anti-EGFL7 polyclonal antibody (R&D systems).  
 
 
Cell adhesion assay 
 
EA.hy926 endothelial-derived cells treated with EGFL7 siRNA or scrambled siRNA 
(negative control) were detached by treatment with trypsin/EDTA and resuspended in DMEM 
containing 1% serum. Cells were plated into 96-well plate and treated with 200 µM of Flag, 
scrambled or E7-C13 peptide for 4 hrs at 37 oC. Cells were then washed three times with PBS 
and fixed with 4% formaldehyde. Cell nuclei were stained with Hoechst (Pierce) and imaged 
under the EVOS f1 inverted fluorescent microscope (AMG). The number of cells that remained 
adhered to the plate was determined using by Volocity, version 4.0. All statistics were performed 
using a one-way ANOVA and Tukey post hoc test. 
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Screening for activation of specific tyrosine kinases using a phospho-RTK profiler array 
system 
 
 HUVECs were detached by treatment with trypsin/EDTA and resuspended in EGM. 
Cells were plated into a T-175 flask and treated with 200 µM of Flag or E7C13 peptide for 4 hrs 
at 37 oC. Cells were harvested and lysed in Array Buffer 1 according to the Human Phospho-
Receptor Tyrosine Kinase (RTK) Array Kit (R&D systems) manufacturer’s guideline. After 
blocking, each phospho-RTK array membranes were incubated with 100 µg of lysate according 
to the manufacturer’s guidelines. Membranes were washed, and incubated with anti-phospho-
HRP. Activated tyrosine kinases were detected by enhanced chemiluminescence (ECL) as per 
manufacturer’s guidelines.  
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5.4 Results 
 
Sequence analysis of EGFL7 protein and identification of E7-C13 peptide 
 
 EGFL7 has a molecular weight of ~30 kDa and is important for a role in vascular 
development and angiogenesis (reviewed in (34)). In search for conserved sequences in EGFL7 
that could be responsible for its function in angiogenesis, we compared the sequences of EGFL7 
protein from six different species: human, cow, mouse, rat, chicken, and dog using the ClustalW 
multiple sequence alignment (Figure 5.1a). We observed that several domains remain highly 
conserved across these species (Figure 5.1a). We then compared the protein sequences of human 
EGFL7 and its paralog, EGFL8 using the ClustalW multiple alignment sequence (Figure 5.1b). 
We distinguished the E7-C14 and the E7-C13 sequences, which are unique to EGFL7 but not 
present in EGFL8, and is conserved across the six species that we analyzed (Figure 5.1a and b). 
In human EGFL7, the E7-C14 peptide is located between amino acids 213 – 226, while the E7-
C13 peptide is located between amino acids 237 – 248 (Figure 5.1c). 
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Figure 5.1. Sequence analysis of EGFL7 protein and identification of E7-C13 peptide. (a) 
EGFL7 protein sequence homology between six different species (human, cow, mouse, rat, 
chicken and dog) using the ClustalW multiple sequence alignment tool. The E7-C14 and E7-C13 
sequences are indicated in a black box. (b) Protein sequence alignment between human EGFL7 
and its paralog, EGFL8 using the ClustalW multiple sequence alignment tool. The E7-C14 and 
E7-C13 sequences are indicated in a black box. (c) Protein structure of EGFL7 (signal peptide: 
orange box, EMI domain: blue box, EGF domain: red box, E7-C14 peptide sequence: purple and 
E7-C13 peptide sequence: green). 
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The inhibition of HUVECs morphogenesis by E7-C13 peptides in vitro 
 
 E7-C14 and E7-C13 were synthesized as described in the methodology section. The 
effects of E7-C14 and E7-C13 peptides on angiogenesis were investigated first using in vitro 
matrigel angiogenesis assay. Human umbilical vein endothelial cells (HUVECs) were allowed to 
spontaneously sprout and form tubes on solid matrigel in the presence of VEGF and bFGF. 
Treatment with E7-C13 resulted in significant decrease in tube formation compared to controls 
(H20 and Flag peptide), while E7-C14 only exhibited a modest inhibition (Figure 5.2a). HUVECs 
treated with either H20 or Flag interacted with each other and formed sprouts, while cells treated 
with E7-C13 remained relatively unchanged (Figure 5.2a). E7-C14 also displayed slight 
inhibition in the level of HUVECs sprouting, although this reduction was not significant 
compared to control. The level of angiogenesis was quantified by counting the number of branch 
points formed in each groups. E7-C13 significantly decreased the formation of branch points by 
approximately 4 times (Figure 5.2b). We showed that E7-C13 significantly inhibited endothelial 
cells morphogenesis in vitro.  
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Figure 5.2. E7-C13 inhibits sprouting and tube formation of HUVECs in vitro. (a) In vitro 
angiogenesis assay demonstrating a significant decrease in the level of sprouting and tube 
formation in HUVECs on Matrigel in the presence of VEGF and FGF after treatment with E7-
C13 (but not E7-C14) compared to controls (Flag peptide or H20) (at a concentration of 200 
µM). (b) Bar graph showing the number of branch points that was formed by HUVECs from 
each group. The level of angiogenesis was quantified by counting the number of branch points 
(indicated by arrows). All statistics were performed using a one-way ANOVA and tukey post 
hoc test. 
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Characterization of E7-C13 peptide 
 
Recombinant EGFL7 protein was purified as described in the methodology section. The 
chemical structure of E7-C13 is illustrated in Figure 5.3a. The association of E7-C13 with 
purified EGFL7 protein was determined using surface plasmon resonance (SPR). SPR analysis 
shows that the association of E7-C13 with EGFL7 is significantly stronger than that of control 
peptide, with a 50% maximal binding at saturation (K50) of approximately 30 nM. 
(Supplementary Figure 5.1). To advance to in vivo studies, we examined the plasma stability of 
E7-C13 peptide. E7-C13 was incorporated into 100% human serum, and the amount of peptide 
remaining at each time point was quantified over a period of 7 hrs using high-performance liquid 
chromatography (HPLC). The plasma half-life of E7-C13 was calculated to be approximately 5.5 
hours in 100% serum (Figure 5.3b). 
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Figure 5.3. Synthesis and characterization of E7-C13. (a) Chemical structure and sequence of 
E7-C13. Structure was generated using the ChemDraw software. (b) Serum stability plot 
demonstrating the peptide stability of E7-C13 in 100% human serum. Peptide was treated with 
serum at a final concentration of 50 µg/mL at 37oC. At each time point, 200 µL of serum was 
retrieved, and serum proteins were precipitated in cold ethanol. The supernatant containing the 
peptide was retrieved, frozen in dry ice and lyophilized. Samples were resuspended in 200 µL of 
H20 and 40 µL of MeCN, and analyzed by HPLC. Graph was generated using the linear function 
in GraphPad Prism. The half-life of E7-C13 is 327 minutes (5.5 hrs).  
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E7-C13 inhibits angiogenesis in vivo using the avian CAM model 
 
 Next, the anti-angiogenic efficacy of E7-C13 was evaluated in vivo in the avian 
chorioallantoic membrane (CAM) model. HT1080 cells were cultured onto fiber-mesh to 
stimulate the recruitment of blood vessels from the CAM onto the mesh. Visible blood vessels 
growing into the collagen on-plants containing HT1080 fibrosarcoma cells (Figure 5.4a). E7-C13 
significantly reduced the number of new blood vessels that entered the on-plant at a 
concentration of 200 µM compared to a vehicle control (Figure 5.4b). The level of angiogenesis 
observed upon treatment with E7-C13 is comparable to that of background angiogenesis, which 
occurs in control on-plants.  
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Figure 5.4. E7-C13 inhibits angiogenesis in the avian CAM model. (a) In vivo angiogenesis 
assay demonstrating that E7-C13 inhibits angiogenesis using the chicken chorioallantoic 
membrane (CAM) model. HT1080 cells were cultured onto collagen-containing fiber-mesh to 
stimulate the recruitment of blood vessels from the CAM onto the mesh. A negative control 
group with no HT1080 cells was also used. Visible blood vessels growing into the collagen on-
plants are indicated by red arrows. (b) Bar graph showing the level of angiogenesis observed in 
each group (n > 32). The angiogenic index was quantified by counting the percentage of grids 
within the mesh that contains visible blood vessels (# of squares containing blood vessels/total # 
squares). All statistics were performed using a one-way ANOVA and tukey post hoc test. 
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E7-C13 inhibits angiogenesis in mice using DIVAA 
 
 The anti-angiogenic potential of E7-13 was investigated in mice using the directed in vivo 
angiogenesis assay (DIVAA). Angioreactor tubes (semiclosed silicone cylinders that are 
approximately 1 cm in length) were filled with basement membrane extract (BME). HT1080 
cells were added to stimulate angiogenesis into the angioreactors. E7-C13 significantly inhibited 
the growth of new blood vessels into the angioreactor at a concentration of 200 µM compared to 
a vehicle control (positive control) (Figure 5.5). The level of angiogenesis observed after 
treatment with E7-C13 is comparable to that of background angiogenesis that is observed in 
negative control angioreactors that contained no HT1080 cells.  
 
 
 
 
Figure 5.5. E7-C13 inhibits angiogenesis in mice using the directed in vivo angiogenesis 
assay (DIVAA). Bar graph showing the percent angiogenesis observed in angioreactor tubes (n 
= 8) from each group. Angioreactors were filled with basement membrane extract (BME) and 
HT1080 cells to stimulate angiogenesis. BME (-ve) is a negative control that contained only 
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BME without cells. All statistics were performed using a one-way ANOVA and tukey post hoc 
test.  
 
 
E7-C13 does not alter the adherent property of human endothelial cells.  
 
 A study in zebrafish revealed knockdown of EGFL7 resulted in impaired vascular tube 
formation due to the failure of angioblasts to separate and retain extensive tight junctions (25). It 
was shown that EGFL7 promotes endothelial cell adhesion, although the strength of adhesion 
was significantly weaker compared to other cell adhesion proteins, such as fibronectin and 
collagen (25). This suggests that EGFL7 provides a permissive substrate that predominantly 
favors motility over stable adhesion to allow the local migration of angioblasts during the 
process of tube formation. Because E7-C13 is a peptide that is derived from the sequence of 
EGFL7, we examined whether E7-C13 inhibits angiogenesis through direct impediment of 
EGFL7 activity. Cell adhesion assay using EA.hy926 human endothelial cells treated with Flag 
(control), scramble (control) or E7-C13 peptide (200 µM) shows that E7-C13 did not affect the 
attachment of cells on culture plates (Figure 5.6a). siRNA knockdown of EGFL7 in cells 
significantly decreased cell adhesion (Figure 5.6a). Vinculin staining of EA.hy926 cells reveals 
no difference between cells treated with scramble (control) or E7-C13 peptide in the formation of 
focal adhesions on glass coverslip (Figure 5.6b). 
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Figure 5.6. E7-C13 does not affect cell adhesion of EA.hy926 human endothelial cells. (a) 
Cell adhesion assay showing that E7-C13 (200 µM) does not alter the adherent properties of 
EA.hy926 endothelial cells compared to Flag or scramble peptide. Knockdown of EGFL7 in 
EA.hy926 cells using siRNA significantly decreased cell adhesion (p < 0.01). Cell nuclei were 
stained with Hoechst dye, imaged and counted using the Volocity software (version 6.1.2, 
Improvision). All statistics were performed using a one-way ANOVA and tukey post hoc test. 
(b) Vinculin staining of EA.hy926 cells showing focal adhesion formation on glass coverslip. 
Left panel: Vinculin (orange) and DAPI (blue). Right panel: merged images of vinculin (orange), 
WGA plasma membrane stain (green) and DAPI (blue). Scale bar, 10 µm.  
 
 
RTK activation profile of HUVECs treated with E7-C13 
 
 To elucidate the molecular mechanism in which E7-C13 is modulating angiogenesis, we 
screened an array of 49 different anti-human receptor tyrosine kinase (RTK) antibodies to 
determine the profile of tyrosine kinase activation upon treatment of HUVECs with E7-C13. 
Lysate from HUVECs treated with E7-C13 at a concentration of 200 µM showed differential 
activation of several RTKs compared to that from Flag (control) (Figure 5.7a). The intensity of 
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each spot was quantified using the Volocity software (version 6.1.2, Improvision), and the level 
of phosphorylation of each RTK was compared according to the coordinates displayed in Figure 
5.7b. We observed that E7-C13 treatment results in a decrease in phosphorylation of anaplastic 
lymphoma kinase (ALK), fibroblast growth factor receptor 3 (FGFR3), Axl and vascular 
endothelial growth factor receptor 1 (VEGFR-1).  
 
 
 
 
Figure 5.7. Profiling RTK activation in HUVECs upon treatment with E7-C13. (a) Array 
membranes displaying 49 different anti-human RTK antibodies incubated with lysates from 
HUVECs treated with either control Flag or E7-C13 peptide (200 µM) for 4 hrs (R&D systems). 
Phosphorylated RTKs were detected by incubation with pan anti-phospho-HRP followed by 
treatment with enhanced chemiluminescence. (b) Phospho-RTK array coordinates (left) and their 
respective RTKs (right table).   
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5.5 Discussion and conclusion 
 
 We report here the identification of a novel E7-C13 peptide that is derived from the 
EGFL7 protein sequence that exhibits anti-angiogenesis potential. Initially, we identified two 
different sequences, E7-C14 and E7-C13, which are both highly conserved across several 
different species and unique to EGFL7, but not present in its paralog, EGFL8. Protein sequence 
alignment using the NCBI basic local alignment search tool (BLAST) blastp algorithm reveals 
that these sequences are not found within other human protein sequences. Since EGFL7 is a very 
important regulator of vasculogenesis (reviewed in (34)), we postulated that these unique peptide 
sequences that is highly conserved across multiple species would have biological importance that 
assumes a crucial function in modulating angiogenesis. Out of the two peptides, we found that 
E7-C13 exhibited a much greater anti-angiogenesis potential compared to E7-C14 in in vitro 
angiogenesis assays. 
 
 Here, we describe the synthesis and application of E7-C13 as a first line peptide that is 
directly derived from the sequence of EGFL7 as an angiogenesis inhibitor. This peptide is 
composed of L-amino acids, and with a half-life of ~5.5 hours in human serum, which may 
attribute to the high working peptide concentration that is required for anti-angiogenic effect in 
vivo. Nonetheless, E7-C13 can serve as a parent peptide for further development of novel anti-
angiogenic agents with greater efficacy and potency. As reviewed by Soto and colleague, the 
conversion of peptide to clinically useful drugs often involves chemical modifications, such as 
introduction of D-amino acids, non-natural amino acids and peptide cyclization in order to 
improve peptide stability (35). The efficacy of E7-C13 in inhibiting angiogenesis through 
intravenous administration route is yet to be determined. 
 
 We have established that E7-C13 has a high binding affinity for purified recombinant 
EGFL7 protein through surface plasmon resonance analysis. Since EGFL7 is a secreted protein 
that is mostly deposited onto the ECM, we therefore, postulate that E7-C13 interacts directly 
with EGFL7 on the surface of endothelial cells, leading to the inhibition of its function in 
modulating angiogenesis. Nonetheless, further investigations are required to specifically address 
and validate this hypothesis. EGFL7 has been shown to promote endothelial cell adhesion and 
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the formation of focal adhesions (25). Since we observed that E7-C13 neither affects endothelial 
cell adhesion nor the formation of focal adhesions in vitro, it is possible that E7-C13 represses 
angiogenesis through other EGFL7-signaling pathways without influencing the adherent 
property of cells. 
 
 We sought to uncover the mechanism of action of E7-C13 by screening an array 
containing 49 different receptor tyrosine kinase (RTK) antibodies to simultaneously monitor the 
increase or decrease in phosphorylation of each RTK upon treatment of human endothelial cells 
with E7-C13. We observed that E7-C13 decreases the activity of ALK, FGF3, Axl and VEGFR-
1. ALK has been identified to be a receptor of for the growth factor, Pleiotrophin (PTN) (36) that 
has been implicated to serve as a rate-limiting factor for angiogenesis (37, 38). Overexpession of 
FGFR3 in myeloma and bladder cancer patients is correlated with increased disease 
pathogenesis, poor clinical response and decreased survival (39, 40). Axl has been shown to play 
an important role in angiogenesis and tumorigenesis through the angiopoietin/Tie2 and the 
Dickkopf signaling pathways (41). Similar to the phenotype we observed with E7-C13, Axl 
knockdown results in the impairment of tube formation in human endothelial cells (41). VEGFR-
1 is essential for the organization of embryonic vasculature, and that disruption of of the 
VEGFR-1 gene results in severe abnormalities in blood vessel formation (42). Although there are 
currently no clinically approved drugs that specifically target and hamper the activity of these 
RTKs, inhibitors of these RTKs have exhibited great promises for cancer therapy. For example, 
inhibition of ALK with a potent drug induced regression of established lymphomas (43), while 
monoclonal antibodies against Axl attenuated the growth of non-small cell lung carcinoma 
xenografts (41). These reports strengthen our belief that E7-C13 can serve as a promising anti-
angiogenic agent for treating cancers.  
 
The process that E7-C13 undertakes to deactivate these RTKs is currently unclear, and 
more investigations are required to unveil the exact mechanism that leads E7-C13 to inhibit 
angiogenesis. Uncovering the mechanism of action of E7-C13 could potentially allow us to link 
the function of EGFL7 to specific RTK pathways, therefore giving us insights into novel 
mechanisms by which EGFL7 promotes angiogenesis and tumorigenesis. Identifying the specific 
targets of E7-C13 could also help us establish the potential for using E7-C13 to treat patients that 
are resistant to therapeutic drugs that specifically inhibits other RTK activities. Ultimately, the 
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use of E7-C13 can be expanded to incorporation into nanoparticles to target EGFL7 for potential 
applications in imaging and drug delivery. 
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Chapter 6 
 
Discussion and Conclusion 
 
 
6.1 Summary and significance 
 
Ligand-mediated targeting has revolutionized the field of nanotechnology to facilitate 
early diagnosis, monitoring of disease progression, and drug delivery. My research goals focus 
on the targeting aspect in the development of nanotechnology. This dissertation described the 
strategies that we have designed and utilized to rapidly and accurately discover novel peptides 
for targeting tumors. As metastasis contributes to greater than 90% of cancer mortalities, non-
invasive detection of angiogenic factors expressed during the earliest stages of tumor 
development can aid in the diagnosis of neoplasms before they metastasize. Therefore, my 
research goals involve designing a high-throughput and unbiased ‘beads on a bead’ approach to 
facilitate the isolation of novel ligands against αvβ3 integrin or EGFL7 via screening an OBOC 
combinatorial peptide library.  
 
Conventional high-throughput methods often involve the immobilization of the target 
protein in a specific orientation, thus biasing its display and surface exposure to ligands during 
the screening process. My first research objective was to develop an unbiased multiplex ‘beads 
on a bead’ strategy to isolate, characterize and validate high affinity ligands from one-bead one-
compound (OBOC) libraries (1). This scalable approach enriches for non-canonical ligands and 
incorporates multiple selection and validation parameters, including on-bead binding validation. 
To establish this strategy, we performed proof of principle experiments by exploiting the well-
established affinity of αvβ3 integrin, a protein that is overexpressed on tumors and angiogenic 
blood vessels, for the RGD peptide, a motif found in several ECM proteins. Peptides derived 
from the RGD sequence have been demonstrated to target αvβ3-expressing tumors for non-
invasive imaging. However, RGD peptides have been shown to affect the biology of cancer cells, 
which can lead to more severe tumor progression. We sought to generate peptides targeted to 
αvβ3 integrin that do not contain the RGD motif to allow the detection of nascent tumors without 
affecting the tumor biology. To screen for peptides against αvβ3 integrin, we employed the 
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‘beads on a bead’ method to screen an OBOC library using αvβ3-coated magnetic beads. Positive 
hits consisted of library beads coated with magnetic beads, and these were isolated from the 
negative library beads using either a strong magnet (bulk isolation) or a large particle flow 
cytometry instrument (high-throughput isolation). An on-bead cell assay was used to validate the 
affinities of peptides with native αvβ3 integrin on the cell surface of αvβ3-expressing MDA-435 
breast cancer cells. The hit peptides were cleaved and sequenced "on bead" using a MALDI-
TOF/MS technique that we have previously described (2), and the binding affinities of each 
peptide were determined using surface plasmon resonance (SPR). We reported the discovery of 
novel peptide ligands that target αvβ3 but do not contain the RGD motif, and demonstrated that, 
in contrast to RGD, they did not affect cancer or endothelial cell biology (1). This strategy is 
useful for both laboratory-based benchtop or large scale high throughput approaches. The 
peptides identified here represent novel targeting agents for integrins that can be applied to 
cancer imaging or treatment without the risk of increased tumor invasion and metastasis. 
 
Several studies have demonstrated much success in using whole cell binding assays to 
screen OBOC libraries to isolate ligands specific to cell surface receptors of numerous human 
cancer cell lines (3), ie. Jurkat T-leukemia cells (4), T-lymphoma cell (5), and breast cancer cells 
(6). Nonetheless, conventional methods for isolating few positive hits from billions of OBOC 
library beads through manual techniques remain impractical and challenging. The COPAS large 
particle biosorter carries great potential for high-throughput and rapid isolation of surface 
binding ligands from a random OBOC library. However, the biggest challenge associated with 
this strategy is the dissociation of cells from the beads upon flowing them through the tubes of 
the instrument. Overcoming this issue will enable an easy and high-throughput automated sorting 
of high-affinity ligands from OBOC libraries. We showed that bound cells can be reversibly 
cross-linked onto beads through chemical fixation, and then easily sorted using the COPAS 
biosorter without affecting the sequence deconvolution of on-bead peptides using MALDI-
TOF/TOF mass spectrometry. This finding enables one to discover novel affinity ligands through 
screening combinatorial libraries against living cells, and obtain peptide sequences from positive 
hits very quickly.  
 
EGFL7 is a protein that is dramatically upregulated in the endothelium of tumors. The 
expression of EGFL7 correlates with poor prognosis in several different cancers. Studies have 
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shown that the vasculature in prostate cancers have shown that men with the most irregularly 
shaped vessels are 17.1 times more likely to develop lethal disease, and these vessels specifically 
express EGFL7. Taken together, these findings show that EGFL7 is an important biomarker for 
clinically relevenat neoplasms and metastases. We hypothesize that molecular imaging using 
peptides targeted to EGFL7 will allow for non-invasive detection of early cancers and distant 
metastases. To test this, we screened an OBOC library to identify novel high-affinity peptide 
ligands of EGFL7 through screening a combinatorial peptide library using the ‘beads on a bead’ 
approach (1). We coated magnetic nanobeads with full-length recombinant EGFL7, mixed these 
with the peptide library beads that each displayed a unique octapeptide, and isolated the most 
highly interacting library bead "hits" with a magnet. An on-bead cell-binding assay was used to 
validate the peptide hits using an EGFL7-expressing HT1080 fibrosarcoma cell line. Hit peptides 
were then sequenced using a novel in-house MALDI-TOF/MS technique (2), and their binding 
affinity to EGFL7 was quantified using surface plasmon resonance (SPR). A high-affinity 
peptide ligand, E7-p72 was shown to bind and be taken up by cancer cells and endothelial cells 
in an EGFL7-dependent manner, and the knockdown of EGFL7 or the presence of an excess of 
unlabeled peptide significantly decreased this uptake. This lead candidate could provide a basis 
for a new generation of sensitive molecular imaging agents for the early and non-invasive 
diagnosis of cancers. 
 
Our growing understanding of EGFL7 function has also led us to design and generate a 
peptide that inhibits angiogenesis. To do this, we searched for bioactive peptides derived from 
EGFL7 with the hypothesis that they would interfere with EGFL7 function, leading to the 
inhibition of angiogenesis. We identified bioactive EGFL7 sequences by searching for highly 
conserved motifs across several species, but are not present in the paralog of EGFL7, the EGFL8 
protein. Particularly, one high-affinity ligand, E7-C13 inhibited angiogenesis in vitro (using 
human primary endothelial cells) and in vivo (using both the avian embryo chorioallantoic 
membrane (CAM) and mouse models). This peptide could provide a basis for a new generation 
of therapeutic agents for locally advanced cancers. 
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6.2 Future work 
 
We have reported here a versatile ‘beads on a bead’ screening strategy for the discovery 
of novel affinity ligands from OBOC libraries, and demonstrate its utility by identifying several 
high affinity peptide ligands for αvβ3 integrin. As described in ‘chapter four’ of my thesis, we 
have also used this approach to screen for peptides that target the EGFL7 protein, confirming its 
usefulness in the identification of novel ligands against any target protein of interest. We intend 
to continue using this approach to screen against several different cell surface targets. 
 
The αvβ3-targeting peptides, LCE62 and LCE64 described in this dissertation could 
provide a basis for a new generation of tumor targeting agents to image newly developed tumors, 
or treat locally advanced cancers. Although these peptides target breast cancer cells in vitro in a 
αvβ3 dependent manner without affecting the biology of the cells, the efficacy of these peptides 
to target αvβ3-expressing tumors in vivo still needs to be further evaluated. In order to do this, 
serum stability assays need to be performed to establish the half-lives of these peptides. As these 
peptides consist only L-amino acids, modifications on the sequences with non-natural amino 
acids may be required to enhance the stability of peptides in serum. Ultimately, these peptides 
can be conjugated with a fluorophore, or attached onto the surface of nanoparticles loaded with 
contrast agents and/or therapeutics for applications in molecular imaging and/or drug delivery of 
αvβ3-expressing cancers. 
 
 We have also demonstrated that screening an OBOC combinatorial library directly using 
fluorescently labeled cells, followed by a rapid automated isolation of high affinity hits using the 
COPAS large-scale flow cytometer can be achieved through chemical cross-linking of the cells 
onto hit beads prior to sorting. In collaboration with Dr. Leonard Luyt and Dr. Eva Turley from 
the London Regional Cancer Centre, we have used this approach to screen for novel peptides 
against the receptor for hyaluronic acid mediated motility (RHAMM) using fluorescently labeled 
RHAMM-positive cells (green) and RHAMM-knockout cells (red). RHAMM is a cell surface 
receptor for hyaluronan, and regulates growth factor signaling (7, 8). RHAMM is also required 
for cellular locomotion of ras-transformed fibrosarcoma cells, T-lymphocytes, malignant B cells 
and breast carcinoma cells (9). Therefore, identify novel peptides with high affinity for RHAMM 
can be useful for the development of molecular imaging probes to facilitate the diagnosis and 
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monitoring of certain cancers. Hit beads that interacted most strongly with green cells, but not 
red cells were isolated, and the peptides were sequenced (2). These peptides are currently being 
further characterized and evaluated for their ability to target RHAMM-expressing cells for the 
development of new molecular imaging agents in Dr. Turley’s laboratory.  
 
 We have reported the discovery of a novel EGFL7 targeting ligand, E7-p72, as a first line 
peptide for molecular imaging of EGFL7 expressing cells. While E7-p72 effectively targets 
cancer cells and endothelial cells in an EGFL7 dependent manner in vitro, we are in the process 
of evaluating the ability of E7-p72 to bind EGFL7-expressing solid tumors as well as angiogenic 
sprouts in mice. Currently, we are developing EGFL7-targeting CPMV nanoparticles (CPMV-
PEG-E7-p72) for molecular imaging through the incorporation of E7-p72 peptide and near 
infrared fluorophore onto the surface of the viral capsid. We intend to establish a xenograft 
model of human prostate cancer in nude mice, and then evaluate the ability of CPMV-PEG-E7-
p72 to specifically target and illuminate the site where the tumor is developing. At the endpoint, 
tumors will be resected, frozen and cryo-sectioned. Sections will be stained with anti-mouse 
PECAM antibody to visualize the endothelium, and the localization of CPMV-PEG-E7-p72 will 
be determined through confocal microscopy. In addition, in collaboration with Dr. Leonard Luyt, 
we are also in the process of labeling E7-p72 with radionuclides (ie. gallium-68) to develop new 
imaging probes for positron emission tomography (PET) imaging of tumor development and/or 
angiogenesis.   
 
On going work is also currently underway to develop and characterize a 2nd generation 
peptide, E7-p72(Daa) that incorporates flanking D-histidines residues that has a significantly 
improved serum stability property. The binding affinity of E7-p72(Daa) to EGFL7, as well as its 
uptake by EGFL7-expressing cells in vitro and by tumor cells and/or angiogenic vessels in vivo 
still needs to be further evaluated.  
 
 We also described identification of E7-C13, a first line peptide directly derived from the 
sequence of EGFL7 that inhibits angiogenesis. Although we have demonstrated that E7-C13 
inhibits angiogenesis in vitro (using matrigel morphogenesis assay) and in vivo (using the 
collagen on-plant avian embryo CAM model (10) and the directed in vivo angiogenesis assay in 
mice), the efficacy of E7-C13 in inhibiting angiogenesis through intravenous administration 
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route is yet to be determined. We are currently in the process of identifying the signaling 
pathways in which E7-C13 uses to inhibit angiogenesis by monitoring the changes in 
phosphorylation level in 49 different receptor tyrosine kinases (RTK) upon treatment of human 
endothelial cells with E7-C13. Our preliminary findings show that E7-C13 decreases the activity 
of anaplastic lymphoma kinase (ALK), fibroblast growth factor receptor 3 (FGF3), Axl and 
vascular endothelial growth factor receptor 1 (VEGFR-1). Efforts to validate these results 
through western blot analyses are currently in progress.  
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Supplementary figures 
 
 
From Chapter 2 
 
 
 
 
Supplementary Figure 2.1. LCE60, LCE62 and LCE64 have high affinity for αvβ3 integrin. 
Association and dissociation curves generated from the interaction and dissociation of RGD, 
LCE60, LCE61, LCE62, and LCE64 with αvβ3 integrin using the SPRimager II (GWC 
Technologies). Association curves were obtained by exposing peptides immobilized onto the 
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SPR chip with αvβ3 integrin. At t = 1900s, the dissociation curves were obtained by washing the 
chip with only buffer. The fitted curves were generated using the ‘association-then-dissociation’ 
equation in GraphPad Prism, version 5.0. 
 
 
From Chapter 3 
 
 
 
Supplementary figure 3.1. Cells remained bound onto the RGD-containing library bead 
after fixation and sorting. TentaGel beads containing a series of RGD-containing peptides 
incubated with MDA-MB-435 GFP cells (left), fixed with 3% formaldehyde (middle) and sorted 
using the COPAS biosorter (right).   
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Supplementary Figure 3.2. Establishing the sorting parameters for the remaining test 
library beads coated with intact cells. Dot plot showing the the cell-bead population and 
sorting profiles. The upper panel shows the two distinct bead and cell population (indicated by 
arrows) and the beads were gated for sorting. The bottom panel shows the green fluorescence 
intensity of each bead. The sort gate was established using negative control TentaGel beads that 
has undergone cell treatment, fixation and washes so that only beads with cells attached (higher 
fluorescent intensities) were sorted. RGD-containing TentaGel beads with MDA-MB-435 GFP 
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were then inserted into the COPAS instrument, and beads with the highest association with cells 
were sorted into a 96-well plate.  
 
 
 
 
 
Supplementary Figure 3.3. On-bead MALDI-TOF/TOF MS sequencing of the remaining 
test peptides before and after fixation. MS/MS spectra of RGD-containing peptides before 
fixing with formaldehyde (left), and after fixing plus sorting (right). Peptide sequences from both 
samples were successfully attained. Fragments labeled bja and yja were calculated by 
complementarity. 
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From Chapter 4 
 
 
 
 
 
Supplementary Figure 4.1. E7-p72 and E7-p74 have nanomolar affinity for EGFL7 
protein. Association and dissociation curves generated from the interaction and dissociation E7-
p72 and E7-p74 with purified EGFL7 (15.6 nM) using the SPRimager II (GWC Technologies). 
Association curves were obtained by exposing peptides immobilized onto the SPR chip with 
αvβ3 integrin. At t = 1700s, the dissociation curves were obtained by washing the chip with 
binding buffer. The fitted curves were generated using the ‘association-then-dissociation’ 
equation in GraphPad Prism, version 5.0. The KD values for each peptide was also calculated and 
indicated in this plot. 
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Supplementary Figure 4.2. Characterization of E7-p72 and E7-p72(Daa) in preparation for 
in vivo studies using human prostate cancer xenograft mouse model. (a) Fluorescence images 
showing the uptake of FITC-E7-p72 and FITC-AGD (negative control) (final concentration of 
3.3 µM) by HT1080 cells. Left panels: FITC signal from peptide uptake (green). Right panels: 
merged images of brightfield image, nuclei staining (red) and FITC-conjugated peptide (green). 
(b) Bar graph generated from ELISA-based E7-p72 alanine scan study. E7-p72 mutants were 
produced by substituting each amino acid in the E7-p72 sequence with an alanine residue. 
Peptides were immobilized onto a maleimide-activated 96-well plate and incubated with purified 
EGFL7. Level of EGFL7 in each well was detected using anti-EGFL7 antibody, followed by 
TMB substrate. The plate was inserted into a microplate reader, and values were obtained at 450 
nm. (c) Serum stability curves demonstrating the peptide stability of E7-p72 and E7-p72(Daa) in 
100% human and mouse serum. E7-p72(Daa) contains the same sequence as E7-p72, with the 
exception that both flanking L-histidine residues were substituted with D-histidines. Peptides 
were treated with serum at a final concentration of 50 µg/mL at 37oC. At each time point, 200 µL 
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of serum was retrieved, and serum proteins were precipitated in cold ethanol. The supernatant 
containing the peptide was retrieved, frozen in dry ice and lyophilized. Samples were 
resuspended in 200 µL of H20 and 40 µL of MeCN, and analyzed by HPLC. Graph was 
generated using the exponential function in Microsoft Excel. The half-lives of each peptide are 
indicated.  
 
 
From Chapter 5 
 
 
 
 
Supplementary Figure 5.1. E7-C13 has high binding affinity for recombinant EGFL7 
protein. Association curves generated from the interaction of E7-C13 or control peptide with 
EGFL7 using the SPRimager II (GWC Technologies). Association curves were obtained by 
exposing peptides immobilized onto the SPR chip with EGFL7 at different concentrations (1 nM, 
20 nM, 50 nM and 100 nM). At t = 600s (10 mins), the percent change in reflectivity (%R) was 
plotted against the concentration of EGFL7 (nM) to generate an association curve using the 
GraphPad Prism, version 5.0. 
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Honour’s Research Project (Jan – Apr, 2007)  
Department of Molecular and Cellular Biology, University of Guelph  
• Investigated bacterial exotoxins, a class of virulence factors produced by pathogenic 
bacteria that are toxic to eukaryotic cells for the potential development of 
therapeutics against bacterial infections and diseases  
• Solubilized and purified a novel exotoxin called Thermotoxin for the ultimate goal of 
obtaining its crystal structure  
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Research Assistant - Funded by NSERC USRA (May – Aug, 2005) 
Department of Chemistry, University of Guelph  
• Investigated Ruthenium-based catalysts for the conversion of waste products to more 
useful sources of energy in the oil industry 
• Worked independently on an assigned research project by performing various 
experiments in effort to synthesize catalysts to be tested 
• Successful in obtaining crystals for structural analysis of two different catalysts  
 
 
AWARDS AND SCHOLARSHIPS 
 
Award/Scholarship 
 
Value 
(CND$) 
per year 
Level Type Location Period 
held 
Ontario Graduate 
Scholarship 
5, 000 Provincial Academic Ontario Sept 2011 – 
Aug 2012 
AACR-Bristol-Myers 
Squibb Oncology 
Scholar-in-Training 
Awards 
1, 000 International Research Canada Apr 2011 
Graduate Research 
Thesis Award 
1, 020 Institutional Research University of 
Western 
Ontario 
Feb 2011 
Molecular Imaging 
Travel Award 
1500 Institutional Research University of 
Western 
Ontario 
Sept 2011 
Graduate Research 
Thesis Award  
840 Institutional Research University of 
Western 
Ontario 
Sept 2010 
Molecular Imaging 
Travel Award 
1500 Institutional Research University of 
Western 
Ontario 
Sept 2010 
WMIC 2010 Travel 
Stipend 
650 International Research Canada Sept 2010 
Graduate Research 
Thesis Award  
750 Institutional Research University of 
Western 
Ontario 
Jan 2010 
 
Bronze W Award 
 
- Institutional Varsity University of 
Western 
Ontario 
Apr 2010 
CIHR STP (PhD) 25,100 National/Institutional Research University of 
Western 
Ontario 
Sept 2009 - 
current 
TBCRU (PhD) 2, 528 Institutional Research University of 
Western 
Ontario 
Sept 2009 - 
current 
WMIC Travel Award  750 Institutional Research University of 
Western 
Ontario 
Sept 2009 
OUA Academic 
Achievement 
 
- Provincial Varsity University of 
Western 
Ontario 
Sept 2008 - 
current 
Nano DDS Travel 
Award 
500 International Research University of 
Toronto 
Oct 2008 
    University of Sept 2008 – 
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CIHR STP (MSc) 25, 700 National/Institutional 
 
Research Western 
Ontario 
Aug 2009 
 
TBCRU (MSc) 
 
4, 028 
 
Institutional 
 
 
Research 
University of 
Western 
Ontario 
Sept 2008 – 
Aug 2009 
Schulich Scholarship  
4, 704 
 
Institutional 
 
Academic 
University of 
Western 
Ontario 
Sept 2007 – 
current 
WGRS Medical 
Biophysics 
 
8, 316 
 
Institutional 
 
Academic 
University of 
Western 
Ontario 
Sept 2007 – 
current 
NSERC USRA 
 
4, 500 National Research University of 
Guelph 
May 2005 – 
Aug 2005 
Queen Elizabeth’s 
Aiming for the Top 
3, 500 Provincial Academic University of 
Guelph 
Sept 2003 – 
Apr 2007 
Dean’s Honour List - Institutional Academic University of 
Guelph 
Sept 2003 – 
Apr 2007 
University of Guelph 
Entrance 
Scholarship 
 
1, 000 
 
Institutional 
 
Academic 
 
University of 
Guelph 
 
Sept 2003 – 
Apr 2004 
 
AACR = American Association of Cancer Research  
CIHR STP = Canadian Institutes of Health Research Strategic Training Program 
Nano DDS = Nanomedicine and Drug Delivery 
TBCRU = Translational Breast Cancer Research Unit 
WGRS = Western Graduate Research Scholarship 
WMIC = World Molecular Imaging Conference 
NSERC USRA = Natural Sciences and Engineering Research Council of Canada Undergraduate Student Research 
Awards 
 
 
CONTRIBUTIONS TO RESEARCH AND DEVELOPMENT 
 
 
Publication 
 
1. Cho, C.F., Amadei, G., Breadner, D., Luyt, L. and Lewis, J.D. (2011) The discovery of 
novel integrin ligands from combinatorial libraries using a multiplex ‘beads on a bead’ 
approach. Nano Letters (ACS publication).  
 
2. Cho, C.F., Ablack, A., Leong, H.S., Zijlstra, A. and Lewis, J.D. (2011) Evaluation of 
nanoparticle uptake in tumors in real time using intravital imaging. Journal of Visualized 
Experiments. http://www.jove.com/details.php?id=2808&status=a4814k 
 
3. Azad, B.B, Cho, C.F., Luyt, L. and Lewis, J.D. (2012) Synthesis, radiometal labeling and 
in vitro evaluation of a targeted PPIX derivative. Applied Radiation and Isotopes. 70: 505 
– 511. 
 
4. Steinmetz, N.F., Cho, C.F., Ablack, A., Lewis, J.D., and Manchester, M.M. (2011) 
CPMV nanoparticles target surface vimentin on cancer cells. Nanomedicine. 6: 351-364 
 
5. Esguerra, K.V.N., Zhang, J., Cho, C.F., Lewis, J., Turley, E. A., and Luyt. L.G. (2010) 
Tubulin derived peptides as optical imaging probes targeting RHAMM. 
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6. Amadei, G., Cho, C.F., Lewis, J.D, and Luyt, L. (2010) A fast, reproducible and low-cost 
method for sequence deconvolution of “on-bead” peptides via “on-target” MALDI-
TOF/TOF mass spectrometry. Journal of Mass Spectrometry. 45: 241-51. 
 
 
Patent 
 
1. Cho, C.F., Lewis, J.D, and Luyt, L. (2012) Polypeptides and methods for inhibiting 
angiogenesis. 
 
 
Book chapter (Submitted) 
 
1. Wen, A., Cho, C.F., Lewis, J.D., and Steinmetz, N.F. Viral based nanoparticles in 
imaging. Nanotechnology in Biological Imaging. John Wiley and Sons. 
 
 
Manuscripts in preparation 
 
1. Cho, C.F., Azad, B., Luyt, L. and Lewis, J.D. (2012) A cell-based approach to screen for 
imaging ligands from combinatorial peptide libraries.  
 
2. Cho, C.F, Nsiama, T., Luyt, L. and Lewis, J.D. Novel peptide ligand against EGFL7, E7-
p72 as a tool for imaging early cancers and angiogenesis. 
 
1. Cho, C.F, Nsiama, T., Luyt, L. and Lewis, J.D. Novel EGFL7 peptide, E7-C13 inhibits 
angiogenesis. 
 
2. Iyengar, B., Fung, L., Cho, C.F., Ablack, A., Ryu, W., and Lewis, J.D. The Drosophila 
ortholog of EGFL7, blade runner, is required for wing structure integrity 
 
3. Fung, L., Cho, C.F., Pink, D., Ablack, A., Schulte, W., Lewis, J.D. EGFL7 blocks tumor 
growth and metastasis by inhibiting angiogenesis in a mir-126 independent manner. 
 
 
Published abstracts 
 
1. Cho, C.F., Steinmetz, N.F., Ablack, A., Manchester, M.M. and Lewis, J.D. (2011) 
Evaluation of viral nanoparticle uptake in vimentin-expressing tumors using intravital 
imaging. 2011 World Molecular Imaging Congress. 
 
2. Cho, C.F., Amadei, G., Breadner, D., Luyt, L. and Lewis, J.D. (2010) The discovery of 
novel non-RGD-containing avb3 ligands for molecular imaging. AACR 102nd Annual 
Meeting 2011. (Received Scholar-in-Training award)  
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3. Cho, C.F., Amadei, G., Breadner, D., Luyt, L. and Lewis, J.D. (2010) The discovery of 
novel non-RGD-containing avb3 ligands for molecular imaging. 2010 World Molecular 
Imaging Congress. (Awarded for excellence)  
 
4. Cho, C.F., Amadei, G., Luyt, L and Lewis, J.D. (2009) Discovery of unique molecular 
imaging probes for avb3-integrin from a combinatorial peptide library using a novel 
‘beads on a bead’ approach. Cancer Microenvironment. 
 
5. Cho, C.F., Amadei, G., Luyt, L and Lewis, J.D. (2009) A novel ‘beads on a bead’ 
approach enables high throughput discovery of ligands for non-invasive molecular 
imaging. 2009 World Molecular Imaging Congress. 
 
6. Cho, C.F., Amadei, G., Luyt, L and Lewis, J.D. (2008) A novel “beads-on-a-bead” 
approach enables high throughput discovery of ligands for targeted molecular imaging 
and drug delivery. Nanomedicine and Drug Delivery Symposium.  
 
7. Azad, B., Cho, C.F., Luyt, L. and Lewis, J.D. (2010) PPIX-RGD Analogues for Dual 
Modality (Optical, PET) Imaging. Pacifichem 2010. 
 
8. Esguerra, K.V.N.,  Zhang, J., Cho, C.F., Lewis, J.D., Turley, E.A., Luyt, L. (2010) 
Tubulin derived peptides as optical imaging probes targeting RHAMM. 2010 SNM 
Annual Meeting.  
 
9. Amadei, G., Cho, C.F., Lewis, J.D. and Luyt, L. (2008) Solid phase synthesis of one 
bead one compound photo-cleavable peptide libraries for ligand screening. 91st 
Canadian Chemistry Conference and Exhibition.  
 
10. Breadner, D., Ablack, A., Cho, C.F., Luyt, L and Lewis, J.D. (2008) High throughput in 
vivo screening of cancer and angiogenesis imaging probes in an avian model of human 
breast cancer. AACR 2008.  
 
 
Oral presentations 
 
1. Cho, C.F., Nsiama, T., Luyt, L. and Lewis, J.D. (2012) Novel peptides targeted against 
EGFL7 as angiogenic inhibitors to treat prostate cancer. Alberta Cancer Foundation’s 
Cancer Research Conference. 
 
2. The Discovery of EGFL7-Binding Peptide Ligands for Molecular Imaging Using a Novel 
"Beads on a Bead" Approach. Oncology Research & Education Day. 2009. (Award 
winning presentation) 
 
3. A novel “beads-on-a-bead” approach enables high throughput discovery of ligands for 
targeted molecular imaging and drug delivery. Nanomedicine and Drug Delivery 
Symposium. 2008. (International) (Awarded for outstanding research in 
nanomedicine) 
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4. A Novel “Beads on a Bead” Approach Enables High Throughput Discovery of Ligands 
for Molecular Imaging. 2008. 2008 Western Research Forum.  
 
 
Poster presentations 
 
1. Cho, C.F., Nsiama, T., Luyt, L. and Lewis, J.D. (2011) Novel peptides targeted against 
EGFL7 inhibit angiogenesis. Oncology Research & Education Day. (Awarded best 
poster) 
 
2. Cho, C.F., Amadei, G., Breadner, D., Luyt, L. and Lewis, J.D. (2010) The discovery of 
novel non-RGD-containing avb3 ligands for molecular imaging. AACR 102nd Annual 
Meeting 2011. (Received Scholar-in-Training award) 
 
3. Cho, C.F., Amadei, G., Breadner, D., Luyt, L. and Lewis, J.D. (2010) The discovery of 
novel non-RGD-containing avb3 ligands for molecular imaging. 2010 World Molecular 
Imaging Congress.   
 
4. Cho, C.F., Amadei, G., Luyt, L and Lewis, J.D. (2009) Discovery of unique molecular 
imaging probes for avb3-integrin from a combinatorial peptide library using a novel 
‘beads on a bead’ approach. Tumour Microenvironment: Progression, Therapy & 
Prevention. 
 
5. Cho, C.F., Amadei, G., Luyt, L and Lewis, J.D. (2009) A novel ‘beads on a bead’ 
approach enables high throughput discovery of ligands for non-invasive molecular 
imaging. 2009 World Molecular Imaging Congress. 
 
6. Cho, C.F., Amadei, G., Luyt, L and Lewis, J.D. (2008) A novel “beads-on-a-bead” 
approach enables high throughput discovery of ligands for targeted molecular imaging 
and drug delivery. Nanomedicine and Drug Delivery Symposium. (Awarded for 
outstanding research in nanomedicine) 
 
7. Cho, C.F., Amadei, G., Luyt, L. and Lewis, J.D. (2008) Non-invasive Imaging of 
Tumour Neovasculature Using EGFL7-targeted viral nanoparticles. Oncology Research 
& Education Day. (Awarded best poster) 
 
 
